 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 1 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
 
CLINICAL STUDY PROTOCOL  
TITLE PAGE  
Protocol Title:  A Phase 2, Randomized, Double -blind, Placebo -controlled 
Study to Evaluate Safety and Antiviral Activity of 
BLD -[ADDRESS_1126554] of Care 
Treatment  
Protocol Number:  B-2660 -204 
Study Drug:  BLD -2660  
Study Indications  Coronavirus disease 2019 (COVID -19) 
Study Phase:  2 
Study Sites  Multiple US sites 
Sponsor Name:  [CONTACT_813584], Inc.  
Legal Registered Address:  [ADDRESS_1126555],   
South San Francisco, CA [ZIP_CODE], [LOCATION_002]  
Sponsor Representative:  Gary Patou, MD  
Chief Medical Officer  
Regulatory Agency Identifier 
Number(s):  IND: 149130  
Approval Date:  08 May 2020  
Version:  3.[ADDRESS_1126556]/Ethics 
Committee.  
The information in this doc ument cannot be used for any purpose other than the evaluation or conduct of the 
clinical investigation without the prior written consent of Blade T herapeutics, Inc.  
 E 
THERAPEUTICS 
DE 
THERAPEUTICS 
Gary Patou, MD 
Chief Medical Offi er 
[EMAIL_15449] SPONSOR SIGNATORY Study drug: BLD-2660 
Protocol Number: B-2660-204 
Date 
Sponsor's Designated Medical Monitor contact [CONTACT_813548]. 
Confidential Page 2 of75 Version 3.0, Amendment 2.0 
08 May 2020 
THERAPEUTICS Study drug: BLD-2660 
Protocol Number: B-2660-204 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_9200]: 
Protocol Number: 
Version and Date: 
Amendment No. 
IND Number: A Phase 2, Randomized, Double-blind, Placebo-controlled 
Study to Evaluate the Safety and Antiviral Activity of 
BLD-2660 in Huspi[INVESTIGATOR_813507]:<l Subjt:cls wilh Rt:ct:nlly Diagnust:<l 
COVID-[ADDRESS_1126557] of this protocol in 
accordance with ethical principles as outlined in the International Council for Harmonisation (ICH) 
guidelines on Good Clinical Practice, any applicable laws and requirements (including Part 54: Financial 
Disclosure by [CONTACT_6230]) and any additional conditions mandated by a regulatory authority 
and/or Institutional Review Board/Independent Ethics Committee (IRB/IEC). 
I acknowledge that I am responsible for the overall study conduct; I approve of and will comply with all 
conditions, instructions and restrictions described in this protocol. I am aware that my adherence to the 
above protocol is mandatory and that any changes in the protocol or consent form, except those 
necessary to eliminate apparent immediate hazards to human subjects, must first be approved in writing 
by <company> and the respective IRB/IEC. 
I also agree that all information provided to me by [CONTACT_1034], including this document, Investigator's 
Brochure, case report form, and verbal and written information, will be kept strictly confidential and 
confined to the clinical personnel involved in conducting the study. It is recognized that this information 
may be related in confidence to the IRB/IEC. I also understand that reports of information about the 
study or its progress will not be provided to anyone not involved in the study other than to the Principal 
Investigator, or in confidence to the IRB/IEC or to the FDA or other legally constituted authority. 
Confidential Date 
1/4.M/r: //4M� '1..£1Jk J)4j&il6.w ✓54-
Institution City, Cou try I 
Page 3 of75 Version 3.0, Amendment 2.0 
08 May 2020 
 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 4 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
DOCUMENT HISTORY  
Document  Date  
Protocol V3.0, Ame ndment 2  08 May 2020  
Protocol V 2.0, Amendment 1  23April 2020  
Original Protocol V1  05 April 2020  
Amendment 2, 08 May 2020  
Overall Rationale for the Amendment:  
Blade  has introduced the following modifications to protocol V3.0, these changes are 
presented in order of appearance :  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis  
2.1 Study rationale  • Update rationale  • To reflect emerging data  
1.1 Synopsis  
3.0 Objectives and Endpoints  • Revise primary endpoints  and add 
new co -primary endpoint  (time  to 
recovery)  
• Add an endpoint  regarding 
remdesivir use  
• Move anti -viral endpoints to 
exploratory endpoints  • To reflect emerging data  
1.2 Schedule of Activities  • Update per changes in the protocol  
• Add D -dimer assessment on Day 5  • To ensure accuracy  and 
consist ency  
2.2 Background  
2.3.2 Benefit  • Update  text regarding approved EUA 
medications  • To reflect emerging data  
5.1.1 Inclusion  criteria  • Delete SARS -CoV -2 infection 
confirmation by [CONTACT_954]  
• Update oxygenation requirements to 
match remdesivir ( SpO 2≤94%)  
• Temperature clarification  • To reflect emerging data 
and change in COVID 
treatment management  
• Typo correction  
5.1.2 Exclusion criteria  • Correct exclusion  criterion no. 5 to 
≥0.75 FiO 2 
• Delete exclusion of antiviral agents 
(e.g. remdesivir)  • Typo correct ion 
• To reflect change in 
COVID treatment 
management  
 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 5 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis  
4.1 Overall design  
6.4 Measure to minimize 
bias: randomization and 
blinding  • Change stratification to remdesivir 
use at study entry  • To reflect change in 
COVID treatment 
management  
6.6 Concom itant therapy  • Allow re mdesivir as concomitant 
medication  
• Move  anti-IL, IL -[ADDRESS_1126558] or use of JAKi  from 
restricted to prohibited medication 
during the study  
• Add EUA agent or compassionate 
use as restricted medication  • To reflect change in 
COVID treatment 
management  
• To reflect change in 
primary endpoint  
8.1 Efficacy Assessments  • Reorganize subsection s to match 
endpoint order . • For consistency across 
the protocol  
8.3 AEs and SAEs  • Add that SAEs will also be collected 
for remdesivir  
 • Per FDA request  
9 Statistical consideration  • Update to reflect changes to 
objectives/endpoints  • For consistency across 
the protocol  
General  • Correct ed typos, formatting, style  
• Align ed changes across protocol  
• Update d Abbreviation (Appendix 6)  • For clarity and 
readability  
 
 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 6 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
TABLE OF CONTENTS  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  ................................ .. 4 
1. PROTOCOL SUMMARY  ................................ ................................ ................  10 
1.1. Synopsis  ................................ ................................ ................................ ............  10 
1.2. Schedule of Activities (SoA)  ................................ ................................ ............  16 
2. INTRODUCTION  ................................ ................................ ............................  21 
2.1. Study Rationale  ................................ ................................ ................................ . 21 
2.2. Background  ................................ ................................ ................................ ....... 22 
2.3. Benefit/Risk Assessment  ................................ ................................ ..................  23 
2.3.1.  Risk Assessment  ................................ ................................ ...............................  23 
2.3.2.  Benefit Assessment  ................................ ................................ ...........................  23 
2.3.3. Overall Benefit: Risk Conclusion  ................................ ................................ ..... [ADDRESS_1126559] of Care  ................................ ................................ ...............................  33 
6.3. Preparation/Handling/Storage/Accountability  ................................ ..................  33 
6.4. Measures to Minimize Bias : Randomization and Blinding  ..............................  33 
6.5. Study Drug Compliance  ................................ ................................ ...................  34 
6.6. Concomitant Therapy  ................................ ................................ .......................  34 
 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 7 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
6.6.1.  Prohibited Medications and Herbal Supplements:  ................................ ...........  [ADDRESS_1126560] 
DISCONTINUATION/WIT HDRAWAL  ................................ ........................  [ADDRESS_1126561] to Follow up  ................................ ................................ ..............................  39 
8. STUDY ASSESSMENTS AND PROCEDURE S ................................ ............  40 
8.1. Efficacy Assessments  ................................ ................................ .......................  40 
8.1.1.  Oxygenation Measures  ................................ ................................ .....................  40 
8.1.2.  Measure of Clinical Support  ................................ ................................ .............  40 
8.1.3.  Clinical Status  Ordinal Score  ................................ ................................ ............  41 
8.1.4.  National Early Warning Score (NEWS)  ................................ ...........................  41 
8.1.5.  Hospi[INVESTIGATOR_813508]  ................................ .............................  42 
8.1.6.  Antiviral Activity  ................................ ................................ ..............................  42 
8.2. Safety Assessments  ................................ ................................ ...........................  43 
8.2.1.  Physical Examinations  ................................ ................................ ......................  43 
8.2.2.  Vital Signs  ................................ ................................ ................................ ........  43 
8.2.3.  Electrocardiograms  ................................ ................................ ...........................  43 
8.2.4.  Clinical Safety Laboratory Assessments  ................................ ..........................  43 
8.3. Adverse Events and Serious Adverse Events  ................................ ...................  44 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Informa tion .............  44 
8.3.2.  Method of Detecting AEs and SAEs  ................................ ................................  45 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ .............  45 
8.3.4.  Regulatory Report ing Requirements for SAEs  ................................ .................  45 
8.3.5.  Pregnancy  ................................ ................................ ................................ .........  45 
8.3.6.  Deaths  ................................ ................................ ................................ ...............  46 
 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 8 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
8.4. Pharmacokinetics  ................................ ................................ ..............................  46 
8.5. Pharmacodynamics and Biomarker Assessments  ................................ .............  46 
9. STATISTICAL CONSIDERATIONS  ................................ .............................  47 
9.1. Statistical Hypothesis  ................................ ................................ ........................  47 
9.2. Sample Size Determination  ................................ ................................ ..............  47 
9.3. Population Analysis S et ................................ ................................ ....................  48 
9.4. Statistical Methods  ................................ ................................ ............................  48 
9.4.1.  General  ................................ ................................ ................................ ..............  48 
9.4.2.  Efficacy Analyses  ................................ ................................ .............................  48 
9.4.3.  Safety and Tolerability Analyses  ................................ ................................ ...... 49 
9.4.4.  Other Analyses  ................................ ................................ ................................ .. 50 
9.5. Interim Analysis  ................................ ................................ ................................  50 
9.5.1.  Data Monitoring Committee  ................................ ................................ .............  51 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ........................  52 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Conside rations  ..........  52 
10.1.1.  Regulatory and Ethical Considerations  ................................ ............................  52 
10.1.2.  Financial Disclosure  ................................ ................................ .........................  52 
10.1.3.  Informed Consent Process  ................................ ................................ ................  53 
10.1.4.  Data Protection  ................................ ................................ ................................ . 53 
10.1.5.  Dissemination of Clinical Study Data  ................................ ..............................  53 
10.1.6.  Data Quality Assurance  ................................ ................................ ....................  54 
10.1.7.  Source Documents  ................................ ................................ ............................  54 
10.1.8.  Study and Site Start and  Closure  ................................ ................................ ...... 55 
10.1.9.  Publication Policy  ................................ ................................ .............................  55 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ .............................  56 
10.3.  Appendix  3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ..............................  57 
10.3.1.  Definition of AE  ................................ ................................ ...............................  57 
10.3.2.  Definition of SAE  ................................ ................................ .............................  58 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ ..................  59 
10.3.4.  Reporting of SAEs  ................................ ................................ ............................  62 
 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 9 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.4.  Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
 ................................ ................................ ................................ ..........................  63 
10.4.1.  Definitions  ................................ ................................ ................................ ........  63 
10.4.2.  Contraception Guidance  ................................ ................................ ...................  64 
10.4.3.  Collection of Preg nancy Information  ................................ ...............................  65 
10.5.  Appendix 5: Cardiac Monitoring Protocol  ................................ .......................  66 
10.6.  Appendix 6: Abbreviations  ................................ ................................ ...............  67 
10.7.  Appendix 7: Protocol Amendment History  ................................ ......................  [ADDRESS_1126562] OF TABLES  
Table  1: Treatment Groups  ................................ ................................ .............................  15 
Table  2: Schedule of Activities  ................................ ................................ .......................  16 
Table  3: Study Drug Admini stered  ................................ ................................ .................  32 
Table  4: A 4-Point Oxygen Ordinal Scale for Severity Categories by [CONTACT_7535] 2/FiO 2 Ratio  40 
Table 5:  A 6-Point Ordinal Score for Assessing Clinical Status  ................................ .... 41 
Table  6: NEW Score  ................................ ................................ ................................ ....... 42 
Table 7:  Adverse Event Reporting Perio ds ................................ ................................ ..... 44 
Table  8: Protocol -Required Laboratory Assessments ................................ .....................  [ADDRESS_1126563] OF FIGURES  
Figure 1  Comparison of IL -6 levels among mild, severe and critical patients with 
COVID -19 Pneumonia  ................................ ................................ .....................  10 
Figure 2  A Mouse Bleomycin (bleo) Pulmonary Fibrosis Model Assessing IL -6 in 
Bronchoalveolar Lavage (BAL) Fluid  ................................ ..............................  11 
Figure  3: BLD -2660 Attenuates Fibrosis Damage in a Mouse Bleomycin (bleo) 
Pulmonary Fibrosis Model  ................................ ................................ ...............  12 
 
 
 Study drug: BLD -2660  
Protocol Number: B -[ADDRESS_1126564] of Care Treatment  
Rationale  
BLD -2660 is a novel, synthetic, orally active, sma ll molecule inhibitor of calpain (CAPN) 1,  
2, and 9 that is selective over the cathepsins as well as other protease families, displays good 
metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) 
inhibition . It is under dev elopment for the treatment of coronavirus disease -19 (COVID -19) 
resulting from infection with Severe Acute Respi[INVESTIGATOR_7531] 2 
(SARS -CoV -2), where there is significant unmet medical need.  
Interleukin 6 (IL -6), a proinflammatory  cytokine , is a key driver  of a cytokine storm that 
plays a significant role in clinical complications and acute lu ng injury  (Dinarello, 2000 ). 
Emerging data indicate that serum lev els of IL -6 are elevated in COVID -19 patie nts and are 
predictive of respi[INVESTIGATOR_1399] ( Coomes, 2020 ; Herold, 2020 ; McGonagle, 2020 ) and 
mortality ( Gong, 2020 ) (Figure 1). IL-6 has been shown to contri bute to l ung damage during 
SARS -CoV infection and t he virus itself is capable of directly inducing its expression 
(Bozym, 2011 ; Yoon, 2008 ). Suppression of pro -inflammatory IL -[ADDRESS_1126565] in many inflammatory diseases, including v iral infections  (Conti, 2020 ).  
Figure 1 Compar ison of IL -6 levels among mild, severe and critical patients with 
COVID -19 Pneumonia  
 
Source: ( Gong, 2020 ) 

 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 11 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
In a mouse model of lung inju ry employing bleomycin , BLD -2660 , at thera peutic doses of 30 
and 100 mg/kg twice per day (BID),  reduced  IL-6 levels  in bronchoalveolar lavage (BAL) 
fluid  (Figure 2). BLD -2660 also  attenuated fibrosis damage as measu red by [CONTACT_813549] 1  in lung tissue ( Figure  3). 
BLD -2660 als o demonstrated target engagement by [CONTACT_813550] s, spectrin, in bron choalveolar cells.  
Figure 2 A Mouse Bleomycin (bleo) Pulmonary Fibrosis Model Assessing IL -6 in 
Bronchoalveolar Lavage (BAL) Fluid  
 
 

 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 12 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Figure  3: BLD -2660 Attenuates Fibrosis Damage in a Mouse Bleomycin (bleo ) 
Pulmonary Fibrosis Model  
 
 
BLD -[ADDRESS_1126566] of BLD -2660 on IL -6 is indepe ndent of the injury, or the affected organ . 
It has been shown that the receptor for SARS -CoV -1 and -2 entry into the cell is angiotensi n-
converting enzyme 2 (ACE -2) (Kuba, 2010 ). ACE -2 and the dime ric calpains (data on file) 
are co -expressed in respi[INVESTIGATOR_813509], the site of both viral entry and predominant 
early lung injury in COVID -19. Inhibition of dimeric calpain activity has not been associated 
with impairment of normal immune functi on. The safe ty and tolerability of BLD -2660 has 
been demon strated in the recently completed Phase 1 single ascending dose (SAD)/multiple 
ascending dose (MAD) B -2660 -101 study.  
As BLD -2660 has been demonstrated to (1) reduce  tissue IL -6 levels  and (2) attenuate lung 
fibrosis damage, it could therefore, potentially  reduce the nonproductive IL-[ADDRESS_1126567] that survivors  of SARS -CoV -2 infection are at risk for chro nic impairment of 
pulmonary function, likely a ttributable to pulmonary fibrosis  secondary to lung injury and 
inflammation.  Although there is not yet available data documenting numbers of patients 
infected with S ARS CoV2 pneumonia who progress to pulmonary fibrosis, epi[INVESTIGATOR_623], 
viral immunology, and current clinical evidence support that pulmonary fibrosis may become 

 Study drug: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 13 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
one of the serious long -term complications of survivors of COVID -19 related pneumonia  
(Wang, 2020b ). 
Thus , BLD -[ADDRESS_1126568] -respons e to 
infection, which  contribut es to morbidity and mortality in COVID -19 but also could reduce 
potential long -term fibrosis and loss of pulmonary function resulting from SARS -CoV  
pneumonia ( Wang, 2020a , Ong, 2005 ). This study will evaluat e BLD -[ADDRESS_1126569] of care (SOC) in hospi[INVESTIGATOR_813510] -
19. 
Objectives and Endpoints  (Primary and Secondary)  
Objectives  Endpoints  
Primary  
• To evaluate clinical benefit of BLD -2660 
in hospi[INVESTIGATOR_813511] -CoV -2 infection  • Time to recovery as de fined by [CONTACT_813551] t or hospi[INVESTIGATOR_7954], whichever occurs first  
 
• To evaluate improvement in oxygenation 
in hospi[INVESTIGATOR_103138] -19 
treated with BLD -2660  • Change from baseline to Day 10 or 
hospi[INVESTIGATOR_2345] , if sooner , in the ratio 
of peripheral  hemoglobin  oxyg en 
saturation to  fraction of  inspi[INVESTIGATOR_1401] 
(SpO 2/FiO 2) 
Secondary  
• To evaluate the safety and tolerability of 
BLD -2660 in the same population  • Incidence  of TEAEs and serious adverse 
events (SAEs)  
• To evaluate improvement in oxygenation  • Improvement from baseline to Day s 10, 
14, 21 and 28  as meas ured by [CONTACT_813552][INVESTIGATOR_813512] (SpO 2/FiO 2), catego rized 
on the 4 --point ordinal scale ( Table  4) 
• Time to discontinuation of oxygen 
supplementation  requirement  
• Mean  SpO 2 for subjects not requiring 
oxygen  supplemen tation at Days 5, 10, 
21 and 28  
• Number  of O2 supplementation free days 
during hospi[INVESTIGATOR_813513]: BLD -2660  
Protocol Number: B -2660 -204 
 
Confidential  Page 14 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Objectives  Endpoints  
• Proportion of subjects who do not requ ire 
oxygen supplementation (sustained for at 
least 24 hours) during hospi[INVESTIGATOR_813514], criteria for removal of o xygen 
supplement ation is defined as resting ([ADDRESS_1126570]) room air saturation >90%  
• Additional efficacy out comes  • Mortality rate during the 2 8-day study 
period  following enrollment  
• Time to hospi[INVESTIGATOR_813515]  
• Proportion of subjects ready to be 
discharged fro m the hospi[INVESTIGATOR_371891] 
28-day study per iod following enrollment  
• Proportion of subjects with re solution of 
fever below entry criteria for 24 hours  (as 
defined in Section  5.1.1 ) by [CONTACT_2006] 10 in 
subjects with fever at baseline  
• Time to resolution of fever below entry 
criteria for 24 hours (as defined in 
Section  5.1.1 ) in subjects with fever at 
baseline  
• Duration (in days) of remdesivi r use in 
subjects starting remdesivir within [ADDRESS_1126571] dose of BLD -2660  
• Change from baseline to Day s 10, 14, 21 
and 28  in clinical status outcome using a 
6-point ordinal scale ( Section  8.1.3 ) 
• Proportion o f subjects reporting each 
6--point  ordinal scale  of the  clinical status  
outcome assessment  
• Change from baseline to Day s 5, 10, 14, 
21 and 2 8 in NEWS score   
• Change from baseline to Day s 10, 14, 21 
and 28  in IL -6 and D -dimer  
 Study drug: BLD -2660  
Protocol Number: B -[ADDRESS_1126572] of care (SOC) therapy i n hospi[INVESTIGATOR_813516] -19 compared to SOC treatment . 
The study will i nclude a Screenin g period, a Treatment period, and a Follow -up period.  
After signing informed consent form (ICF), potential candidates who are hospi[INVESTIGATOR_813517] -CoV -2 will undergo additional screening procedures.  
On Day 1, eligible subjects will be randomized in 2:1 ratio to one of 2 treatment groups, as 
shown in Table  1. Randomization will be stratified by [CONTACT_813553] . All 
subjects will receive study drug in combination with SOC over 10 days (through Day 10/end 
of treatment)  or until hospi[INVESTIGATOR_2345] , if sooner . Subjects  will be followed for at least [ADDRESS_1126573] information on mortality  and force d vital capa city (FVC).  
Subjects will be evaluated as specified in the Schedule of Activities  (SoA; Section  1.2). 
Number of Subjects , Intervention Groups and Duration  
Intervention Groups  
Table  1: Treatment Groups  
Treatment 
Group  Dose Level, Schedule and Route of 
administration  Number of 
subjects  
Activ e BLD -2660 900 mg twic e per day (BID), oral + SOC  80 
Control  Matching placebo, BID, oral + SOC  [ADDRESS_1126574] as follows:  
Study Period  Duration  
Screening period  Up to [ADDRESS_1126575] study follow -up 60 days 
Data Monitoring Committee: Yes 
 Study drug: BLD -2660  
Protocol Number: B -2660-204 
 
Confidential  Page 16 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
1.2. Schedule of Activities  (SoA)  
Table  2: Schedule of Activities  
General Notes:  
• In case of natural disasters or pandemics, some visits/study procedures c an be done via virtual  visits  (e.g., telemedicine or telephone)  or at 
home visits after hospi[INVESTIGATOR_2345]. Refer to study reference manual for more details.  
• Assessments completed as part of standard of care within the protocol defined windows, will not ne ed to be repeated spec ifically for the 
protocol.  
Procedure  Screening  Treatment Period   Follow -up Post-
study 
visit Notes  
  BL Daily 
visits‡ EOT/ET *   EOS  Baseline (B L); End of Treatment 
(EOT), Early termination (ET); End 
of study (EOS)  
‡ If a subject is d ischarged  prior to 
Day 10, they will complete Day 5 
and Day 10 visits assessments  
* This visit will be conducted at 
hospi[INVESTIGATOR_2345], if subject is 
discharged prior to Day 10  Study Day  -3 to -1 1 2-9 10 14 21 28 +60 
days 
from 
EOS  
Visit window (days)     ±1 ±2 ±2 ±2 ±10  
Informed consent  X         
Inclusion and exclusion 
criteria  X X        
Demography  X         
Medical history  X         
Current medical 
conditions  X X     
  Including time from onset of 
symptoms (fever, cough, etc.) to 
study entry, COVID-[ADDRESS_1126576]  
Comprehensive 
physical exam  X   X      
Height and weight  X   X*     *Weight only  
 Study drug: BLD -2660  
Protocol Number: B -2660-[ADDRESS_1126577]-
study 
visit Notes  
  BL Daily 
visits‡ EOT/ET *   EOS  Baseline (B L); End of Treatment 
(EOT), Early termination (ET); End 
of study (EOS)  
‡ If a subject is d ischarged  prior to 
Day 10, they will complete Day 5 
and Day 10 visits assessments  
* This visit will be conducted at 
hospi[INVESTIGATOR_2345], if subject is 
discharged prior to Day 10  Study Day  -3 to -1 1 2-9 10 14 21 28 +60 
days 
from 
EOS  
Visit window (days)     ±1 ±2 ±2 ±2 ±10  
Limited physical exam   X Day 5   X X X  Physical exam will be symptom -
directed exam  
Hematology  X X Day 5  X X X X  Refer to Section  10.2 
Clinical chemistries  X X Day 5  X X X X  Refer to Section  10.2  
INR  X      X  International normal ratio (INR)  
Urinalysis  X      X  Refer to Section  10.2  
Sputum samples and 
nasopharyngeal swab 
for SARS -CoV -2 PCR   X Day 5  X X X X  Samples to be frozen as specified in 
the laboratory manual for viral 
quantification.  
Serum hs CRP and 
ferritin   X Day 5  X X X X  High sensitivity c -reactive protein 
(CRP)  
Reserve blood sample 
for biomarker analyses   X Day 5  X X X X  Date and times to be recorded when 
samples were collected.  
IL-6  X X X X X X  Interleukin 6 (IL-6) 
Serum troponin   X X X X X X   
D-dimer   X Day 5  X X X X   
Pharmacokinetics 
plasma*    Day 5     
  Predose and 1-2 hours postdose  
*if naso -gastic tube (NGT) is 
inserted, PK samples will also be 
collected [ADDRESS_1126578] NGT use.  
 Study drug: BLD -2660  
Protocol Number: B -2660-[ADDRESS_1126579]-
study 
visit Notes  
  BL Daily 
visits‡ EOT/ET *   EOS  Baseline (B L); End of Treatment 
(EOT), Early termination (ET); End 
of study (EOS)  
‡ If a subject is d ischarged  prior to 
Day 10, they will complete Day 5 
and Day 10 visits assessments  
* This visit will be conducted at 
hospi[INVESTIGATOR_2345], if subject is 
discharged prior to Day 10  Study Day  -3 to -1 1 2-9 10 14 21 28 +60 
days 
from 
EOS  
Visit window (days)     ±1 ±2 ±2 ±2 ±[ADDRESS_1126580] 
(WOCBP only)  X        Women of childbearing potential 
(WOCBP)  
12-lead ECG  X X Day 5  X   
X  Electrocardiogram (ECG)  
Can be done more frequently if 
clinically indicated (e.g., elevated 
troponin post baseline level) per 
safety cardiac monit oring 
(Section  10.5) 
X      
  If subjects are on telemetry, ECG is 
only required at screening.  
Vital signs  X X X X X X X  Temperature should be collected 
twice per day (morning and night)  
while hospi[INVESTIGATOR_057] ; same method 
for temperature measurement 
should be used throughout the study  
Chest x -ray or CT scan 
of lungs  (if conducted 
as SOC)  X      X  Computed tomography (CT) , 
standard of care (SOC)  
Same modality to be used 
throughout the study, where 
possible  
 Study drug: BLD -2660  
Protocol Number: B -2660-[ADDRESS_1126581]-
study 
visit Notes  
  BL Daily 
visits‡ EOT/ET *   EOS  Baseline (B L); End of Treatment 
(EOT), Early termination (ET); End 
of study (EOS)  
‡ If a subject is d ischarged  prior to 
Day 10, they will complete Day 5 
and Day 10 visits assessments  
* This visit will be conducted at 
hospi[INVESTIGATOR_2345], if subject is 
discharged prior to Day 10  Study Day  -3 to -1 1 2-9 10 14 21 28 +60 
days 
from 
EOS  
Visit window (days)     ±1 ±2 ±2 ±2 ±10  
SpO 2% X X X X X X X  Peripheral capi[INVESTIGATOR_419927] (SpO 2) is to be recorded 
morning and night  while 
hospi[INVESTIGATOR_057] (coinciding with body 
temperature ) 
Record FiO 2 X X X X X X X  Fraction of inspi[INVESTIGATOR_1401] (FiO 2) 
at each SpO 2 assessment (morning 
and ni ght while hospi[INVESTIGATOR_057])  
FVC        
* X* Forced vital capacity (FVC)  
*Subjects will be requested to 
conduct FVC post study, 
approximately [ADDRESS_1126582] follow -up visit  
APACHE II score   X       APACHE (acute physiology and 
chronic health evaluat ion) 
Hospi[INVESTIGATOR_813518]   X X X X X X  Refer to Section  8.1.5  
Clinical status 6-point 
ordinal scale  X X X X X X X  Refer to Section  8.1.2 
State of consciousness  
X X X X X X X  Level of consciousness: alert (A), 
arousable only to voice (V), or pain 
(P) and unrespon sive (U)  
 Study drug: BLD -2660  
Protocol Number: B -2660-[ADDRESS_1126583]-
study 
visit Notes  
  BL Daily 
visits‡ EOT/ET *   EOS  Baseline (B L); End of Treatment 
(EOT), Early termination (ET); End 
of study (EOS)  
‡ If a subject is d ischarged  prior to 
Day 10, they will complete Day 5 
and Day 10 visits assessments  
* This visit will be conducted at 
hospi[INVESTIGATOR_2345], if subject is 
discharged prior to Day 10  Study Day  -3 to -1 1 2-9 10 14 21 28 +60 
days 
from 
EOS  
Visit window (days)     ±1 ±2 ±2 ±2 ±10  
Randomization   X        
Study drug 
administration   X X X     Treatment to be administered 
during hospi[INVESTIGATOR_813519]    X X      
AE and SAE review   X X X X X X  Adverse event (AEs), Serious AE 
(SAEs)  
Prior and c onco mitant 
medication  X X X X X X X   
Survival status      X X X X  
 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 21 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
2. INTRODUCTION  
2.1. Study Rationale  
BLD -2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, 
and 9 that is sel ective over the cathepsins as well as other pr otease families, displays good 
metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) 
inhibition. It is under development for the treatment of coronavirus disease -19 (COVID -19) 
resulting from infection with Severe Acute Re spi[INVESTIGATOR_7531] 2 ( SARSCoV2 ), 
where there is significant unmet medical need.  
Interleukin 6 (IL -6), a proinflammatory  cytokine , is a key driver  of a cytokine storm that plays a 
significant role in clinical complications and acute lung injury  (Dinarello, 2000 ). Emerging data 
indicate that serum levels of IL -6 are elevated in COVID -19 patients and are pr edictive of 
respi[INVESTIGATOR_1399] ( Coomes, 2020 ; Herold, 2020 ; McGonagle, 2020 ) and mortality ( Gong, 2020 ) 
(Figure 1). IL-6 has been shown to contribute to lung damage during SARS -CoV infection and 
the virus itself is capable of directly inducing its expressi on (Bozym, 2011 ; Yoon, 2008 ). 
Suppression of pro -inflammatory IL -[ADDRESS_1126584] i n many 
inflammatory diseases, including viral infections  (Conti, 2020 ). 
In a mouse mo del of lung injury  employing bleomycin , BLD -2660 , at therapeutic doses of 30 
and 100 mg/kg twice per day (BID),  reduced  IL-6 levels  in bronchoalveolar lavage (BAL) fluid  
(Figure 2). BLD -2660 also  attenuated fibrosis damage as measured by [CONTACT_813554] 1  in lung tissue ( Figure  3). BLD -[ADDRESS_1126585] of BLD -2660 on IL -6 is independent of the injury, or the affected organ.  
It has been shown that the rece ptor for SARS -CoV -1 and -2 entry into the cell is angiotensin -
converting enzyme 2 (ACE -2) (Kuba, 2010 ). ACE -2 and the dimeric calpains (data on file) are 
co-express ed in respi[INVESTIGATOR_790793], the site of both viral entry and predominant early 
lung injury in COVID -19. Inhibition of dimeric calpain activity has not bee n associated with 
impairment of normal immune fu nction . The safety and tolerability of BLD -2660 has been 
demonstrated in the recently completed Phase 1 single ascending dose (SAD)/multiple ascending 
dose (MAD) B2660 -101 study.  
As BLD -2660 has been demonstrated to (1) reduce  tissue IL -6 levels  and (2) at tenuate lung 
fibrosis damage, it could therefo re, potentially reduce the nonproductive IL-[ADDRESS_1126586] that survivors of SARS -CoV -2 infection are a t risk for chronic impairment of 
pulmonary fun ction, likely attributable to pulmonary fibrosis  secondary to lung injury and 
inflammation.  Although there is not yet available data documenting numbers of patients infected 
with SARS CoV2 pneumonia who progres s to pulmonary fibrosis, epi[INVESTIGATOR_623], viral 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 22 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
immunology, and current clinical evidence support that pulmonary fibrosis may become one of 
the serious long -term complications of survivors of CO VID-19 related pneumonia  (Wang, 
2020b ). 
Thus , BLD -[ADDRESS_1126587] -response to 
infection, which  contribut es to morbidity and mortality in COVID -19 but also could reduce 
potential long -term fibrosis and loss of pulmonary function resulting from SARS -CoV 
pneumonia ( Wang, 2020a , Ong, 2005 ). This study will evaluate BLD -2660 as an add -on therapy  
to standar d of care (SOC) in hospi[INVESTIGATOR_813510] -19. 
2.2. Background  
SARS -CoV -2, a positive -sense single -stranded RNA virus of zoonotic origin, is highly 
contagious in humans and is the cause of the ongoing worldwide pandemic o f COVID -19. As of 
April 4, 2020, the SARS -CoV -2 has been responsible for more than 1.2 million  infections and 
70,000 deaths worldwide (data from https://coronavirus.jhu.edu/ ). 
SARS -CoV -2 is transmitted via r espi[INVESTIGATOR_466904] (fomites infectious particles) within a range 
of about [ADDRESS_1126588] with contaminated surfaces. The median incubation period 
was estimated to be 4-5 days, and the majority (97.5%) developed symptoms wi thin 11.5 days 
(CI, 8.2 to 15.6  days) of infection  (Guan, 2020 ; Lauer, 2020 ). Higher viral loads are detected 
soon after symptom ons et, with hi gher viral loads detected in the nose than in the throat  (Zou, 
2020). The mea n vira l load of severe cases was around 60 times higher than that of mild cases, 
suggesting that higher viral loads might be associated with severe clinical outcomes ( Liu, 2020). 
Clinical symptoms of COVID -19 include fever, cough, and dyspnea ( Guan, 2020 ; Jiang, 2 020; 
Rodriguez -Morales, 2020 ; Rothan, 2020 ); a small population of patients also may suffer from 
gastrointestinal symptoms ( Guan, 2020 ; Guo, 2020 ). Radiologic feature s in the lungs  include 
bilateral ground glass opacities on chest x -ray or computed to mography (CT)  (Guan, 2020 ). 
COVID -19 appears to be more prevalent in males than females ( Adhikari, 2020 ). The population 
most at risk are immune -compromised patients such as the elderly, and subjects with co -morbid 
diseases (e.g., diabetes, cardiovascular, cancer). This population is prone to serious outcomes, 
which may be associated with acut e respi[INVESTIGATOR_696] d istress syndrome (ARDS) and cytokine storm 
(Adhikari, 2020 ; Guo, 2020 ). Appr oximately 14% (95%CI 6 .2–21.5%) of hosp italized patients 
had fatal outcomes (case fatality rate, CFR) ( Rodriguez -Morales, 2020 ). 
Initially, the SARS -CoV-2 predominantly infe cts lower airways and binds to ACE -2 on alveolar 
epi[INVESTIGATOR_1663] ( Guo, 2020 ; Kuba, 2010 ). It is a potent inducer o f inflammatory cytok ines. The 
“cytokine storm” or “c ytokine cascade” is the postulated mechanism for organ damage. The 
virus activates immune cells and induces the secretion of inflammatory cytokines and 
chemokines into pulmonary vas cular endothelial cells  (Jiang, 2020 ). 
The FDA has recently approved an emergency use authorization (EUA) for remdesivir to treat 
patients with severe COVID -19. There are no other approved treatments fo r COVID -19, or 
vaccines aga inst SARS -CoV -2. Trea tment management is mainly focus ed on symptomatic and 
respi[INVESTIGATOR_1413]. There are few specific antiviral strategies, but several potent candidates of 
antivirals and repurposed drugs are under urgent invest igation ( Guo, 2020 ). Chloroquine 
phosphate, a drug for treatment of malaria, was shown to have apparent efficacy against  COVID -
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 23 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
19 associated pneumonia in multicenter  clinical trials conducted in China ( Gao, 2020 ), however , 
these studies were not well cont rolled. A recent French study showed no benefit with 
hydroxychloroquine in h ospi[INVESTIGATOR_41374] -19 infections requiring oxygen 
(Mahevas, 2020 ), and another retrospective study in US veterans hospi[INVESTIGATOR_21391] -19 
showed that hydrox ychloroquine increased mortality rate ( Magagnoli, 2020 ). In ad dition, IL-6 or 
IL-6-receptor blocking antibodies like tocilizumab (Actemr a, [COMPANY_002] -Genentech), sari lumab 
(Kevzara, Regeneron), and siltuximab (Sylvant, E[LOCATION_003] Pharma) which  are FDA -approved for 
various conditions , including cytokine r elease syndrome (CRS) , are being  investigated in 
critically ill patients with COVID -19-induced hyp oxia (Ascierto, 2020 ; Conti, 2020 ). Other 
treatments and therapi[INVESTIGATOR_12457], corticosteroids, mechani cal ventilation, 
extracorpo real membrane oxygenation (ECMO) , oxygen therapy, and continuous renal 
replacement techniques (CRRT) ( Jiang, 2020 ). 
A detailed description of the chemistry, pharmacology, efficacy, and safety of BLD -2660 is 
provided in t he Investigator’s Brochure (IB).  
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expecte d adverse events of  BLD -2660  may be found in the  IB. 
2.3.1.  Risk Assessment  
Potent ial Risk of 
Clinical 
Signifi cance  Summary of Data/Rationale for Potential Risk for Study 
Drug BLD -2660  Mitigation 
Strategy  
Elevated troponin  Transient, asymptomatic mild tropo nin elevation was observed 
in 2 healthy volunteers in Phase 1; there were no associated 
clinical, electrocar diographic or imaging  findings and these 
changes resolved without sequalae despi[INVESTIGATOR_147737]. 
Biologically,  calpain inhibition has not been a ssociated with 
cardiac toxicity in animal models, and there was no evidence of 
cardiac toxicity in acute and  chronic toxicology studies.  Safety 
cardiac 
monitoring 
protocol (see 
Section  10.5) 
2.3.2.  Benefit Assessment  
The FDA has recently approved an emergency use authorization (EUA) for remdesivir to treat 
patients with severe COVID -19. There are no other approved medical therapi[INVESTIGATOR_135297] -19. 
BLD -2660 is a candidate  for treating COVID -19 due to the potential protection from lung damage 
which occurs during SARS -CoV-2 infection by  [CONTACT_365801] -6 levels.  
2.3.3.  Overall Benefit: Risk Conclusion  
By [CONTACT_813555], the potential 
risks identified in association with BLD -2660 are justified by [CONTACT_813556] -19. 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 24 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
3. OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primar y 
• To evaluate clinical benefit of 
BLD -2660 in hospi[INVESTIGATOR_813520] -CoV -2 
infection  • Time to recovery as defined by  [CONTACT_813557][INVESTIGATOR_7954] , whiche ver occurs first  
 
• To evaluate improvement in 
oxygenation in hospi[INVESTIGATOR_119800] w ith 
COVID -19 treated with BLD -2660  • Change from baseline to Day 10 or hospi[INVESTIGATOR_7954], if sooner, in the ratio of 
peripheral  hemoglobin  oxygen saturation to 
fraction of inspi[INVESTIGATOR_1401] (SpO 2/FiO 2) 
Secondary  
• To evaluate the safety and tolerability of 
BLD-2660 in the same population  • Incidence of TEAEs and serious adverse 
events (SAEs)  
• To evaluate improvement in 
oxygenation  • Improvement from baseline to Day s 10, 14, 
21 and 28  as measured by [CONTACT_813558][INVESTIGATOR_813512] (SpO 2/FiO 2), categorized on 
the 4 -point ordinal scale ( Table  4) 
• Time to discontinuation of oxygen 
supplementation requirement  
• Mean  SpO 2 for subjects not requiring 
oxygen supplementation at Days 5, 10, 21 
and 28  
• Number of O2 supplementation free days 
during hospi[INVESTIGATOR_059]  
• Proportion of subjects who do not require 
oxygen supplementation (sustained for at 
least 24 hours) during  hospi[INVESTIGATOR_813514], criteria for removal of o xygen 
supplementation is defined as resting ([ADDRESS_1126589]) room air saturation >90%  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 25 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Objectives  Endpoints  
• Additional efficacy outcomes  • Mortality rate during the 2 8-day study 
period  following  enrollment  
• Time  to hospi[INVESTIGATOR_813515]  
• Proportion of subjects ready to be 
discharged from the hospi[INVESTIGATOR_371891] 
28-day study period following enrollment  
• Proportion of subjects with resolution of 
fever below entry criteria for 24 hours  (as 
defin ed in Section  5.1.1 ) by [CONTACT_2006] 10  in 
subjects with fever at baseline  
• Time to resolution of fever below entry 
criteria for 24 hours (as defined in 
Section  5.1.1 ) in subjects with fever at 
baseline  
• Duration (in days) of remdesivi r use in 
subjects starting remdesivir within [ADDRESS_1126590] dose of BLD -2660  
• Change  from baseline to Day s 10, 14, 21 
and 28  in clinical status outcome using a 
6-point ordinal scale (Section  8.1.3 ) 
• Proportion o f subjects reporting each 6-
point  ordinal scale of the  clinical  status 
outcome assessment  
• Change from baseline to Days 5, 10, 14, 21 
and 28 in NEWS score  
• Change from baseline to Day s 10, 14, 21 
and 28  in IL -6 and D -dimer  
Exploratory  
• Other efficacy outcom es • Proportion of subjects who require 
mechanical ventilation after study entry  
• Number of ventilator -free days to Day 21  
• Proportion of subjects with ICU transfer 
and/or ventilator dependence during the 28-
day study period following enrollment  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 26 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Objectives  Endpoints  
• The time to a NEWS of ≤ 2 and maintained 
for 24 hours  
• Change in  NEWS from baseline to Days 3, 
5, 8, 10, 14, 21  and 28  in NEWS  
• To evaluate antiviral activity of 
BLD -2660 in the same population  • Proportion of subjects who are 
SARS --CoV -2 virus free by [CONTACT_2006] 10/EOT  
or hospit al discharge, whichever is sooner  
• Time to eradication of SARS -CoV -2 
• Change from baseline in SARS -CoV -2 
viral load at Days 5, 10, 14 , and 28  
• Other safety outcomes  • Clinically relevant changes from baseline 
in electrocardiogram (ECG), and clinical 
laboratory  values  at each post baseline 
timepoint  
• Proportion of subjects with clinically 
significant drug-related troponin elevations 
that have repeat elevation upon 
confirmatory testing as adjudicated by [CONTACT_813559] 10 -day trea tment period  
• To assess population pharmacokinetics 
(PK) characteristics  of BLD -2660  • BLD -2660 plasma con centrations  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126591] of care (SOC) therapy in hospi[INVESTIGATOR_813516] -19 co mpared to SOC treatment . 
The study will include a Screening period, a Treatment period, and a Follow -up period.  
After signing informed consent form (ICF ), potential candidates who are hospi[INVESTIGATOR_813521] -CoV -[ADDRESS_1126592] s will be randomized in 2:1 ratio to one of 2 treatment groups, active or 
control , as shown in Table  1. Randomiza tion will be stratified by [CONTACT_813560] . All 
subjects will receive study drug in combin ation with SOC over 10 days (through Day 10/end of 
treatment)  or until hospi[INVESTIGATOR_2345], if sooner . Subjects will be followed for at least [ADDRESS_1126593] information on mortality  and force d vital capacity (FVC).  
Subjects will be evaluated as specified in the Schedule of Activities  (SoA; Section  1.2). 
4.2. Scientific Rationale for Study Design  
This Phase 2, randomized, double -blind, placebo -controlled study compares 2 tre atment groups, 
active and control. The study drug will be administered as add -on therapy to SOC as currently 
there are no approved treatments for this potentially lethal disease.  
4.3. Justification for Dose  
The BLD -2660 dose selected for this study is 900 mg BI D is based on nonclinical and clinical 
studies as follows:  
• No maximum tolerated dose has been established due to saturation of abso rption at 
doses above 900 mg. After a single 900 mg dose or 900 mg BID for 2 weeks, BLD -
2660 was well -tolerated . 
• A threshold plasma concentration ≥ 400 ng/mL was associated with efficacy in the 
mouse bleomycin model of idiopathic pulmonary fibrosis (IPF). Based upon the 
similarity of the IC 50 of BLD -2660 in mice and humans (474 nM and 170 nM, 
respectively) and similar pharmacokinetics (PK) curves, the anticipated threshold 
exposure in humans for target engagement is likely to be similar to that seen in the 
mouse. The 900mg dose demonstrated plasma exposure (C max) at or above the 400 
ng/ml for up to 60 minutes on Day 1 a nd exposures were lower at Day 7 and 14.  
• BID dosing is also proposed to maximize the time above the plasma concentration 
associated with efficacy in the animal models . 
• The [ADDRESS_1126594] to the no observed 
adverse e ffects level (NOAEL) doses administered in the rat and dog with a 10 -fold 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 28 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
safety profile when comparing C max and AUC values from the two chronic Good 
Laboratory Practice (GLP) repeated dose toxicology studies . 
For additional details, refer to the Investig ator Brochure.  
4.4. Study Duration  
For each subject the study is expected to last as follows:  
Study Period  Duration  
Screening period  Up to [ADDRESS_1126595] completed the study if he/she has completed all phases of the 
study including the last visit  on Day [ADDRESS_1126596]  in the study.  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126597] meet all the following:  
Age 
1. At least [ADDRESS_1126598] 2 days : 
a. Fever defined as a body temperature of ≥  38.0 °C oral, or ≥ 38.3 ° C rectal , ≥37.7 °C 
forehead  or ≥38.7°C  aural (axillary temperatures are not  allowable) ; 
b. Cough;  
c. Fatigue;  
d. Shortness of breath.  
4. Radiographic evidence (chest x -ray or CT  scan) of one the following:  
a. Ground -glass opacities, or  
b. Local or bilateral patchy infiltrates, or  
c. Interstitial pulmonary infiltrates.  
5. Oxygen requirements:  
a. SpO2 ≤ 94% on ambient air  
OR 
b. Requires supplemental oxygen administration by [CONTACT_371932], simple face mask, 
or other similar oxygen delivery device . 
Sex 
6. Male and/or female subjects . 
Contraception use by [CONTACT_813561].  
7. All subjects (male or female) who are of childbearing potential must agree to use highly  
effective contraception during the study. Female subjects and male partners of female 
subjects must continue to use highly effective contraception for [ADDRESS_1126599] agree not to donate sperm during this time.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 30 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Note: Abstinence is acceptable if this is the usual lifestyle and  preferred 
contraception for the subject.  
Note: Ethinyl estradiol is the primary estrogen used in hormonal contraceptives . The 
progestin component consists of norethindrone, levonorgestrel, norgestrel, 
norethindrone acetate, ethynodiol diacetate, norgestim ate, desogestrel, and 
drospi[INVESTIGATOR_187306]. As BLD -2660 is a weak CYP3A4 inducer, exposure to both the 
estrogen and progestin components in hormonal contraceptives may be decreased, 
resulting in an increased risk of pregnancy . As such, it is recommended that subje cts 
who are on hormonal contraceptives  for birth control should use an alternate means 
of contrace ption (condoms, diaphragms, intrauterine device ( IUD), other barrier 
methods, sexual abstinence, etc.) during participation in the study . 
8. Women of childbearin g potential must have a negative serum pregnancy test at Screening 
within [ADDRESS_1126600] be postmenopausal (defined as cessation of 
regular menstrual periods for at least 1 yea r 
Informed Consent  
10. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the ICF and in this protocol . 
5.1.2.  Exclusion Criteria  
Subjects will be excluded from study participat ion if they meet any of the following:  
Medical Conditions  
1. Active bacterial  pneumonia infection  
2. Known active tuberculosis (TB).  
3. History of Child -Pugh B or C cirrhosis.  
4. History of ischemic heart disease or myocardial inf arction or acute coronary syndrome.  
5. Subjects  requiring supplem ental  oxygen  ≥0.[ADDRESS_1126601] dose of study drug . 
Diagnostic Assessments  
8. The following laboratory parameters are excluded:  
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 x upper 
limit of normal (ULN);  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 31 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
• Creatinine clearance < 50 mL/min . 
Prior Therapy  (refer to Section  6.6 for allowed, prohibited and restricted therapy  during 
the study)  
9. Requiring, or expected to require mechanical ventilation at screening.  
10. Treatment with c hloroquine  or hydroxychloroquine  at study entry.  
11. Treatment with anti -IL-6, anti -IL-6 receptor antagonists, or with Janus kinase inhibitors 
(JAKi) in the past 30 days or plans to receive during the study period.  
Prior/Concurrent Clinical Study Experience  
12. Participation in any other clinical study of an experimental  drug treatment for COVID -[ADDRESS_1126602] dose of study drug.  
Note: Subjects participating in an observational study are an exception to this crite rion and 
may qualify for the study with Sponsor approval.  
Note:  Subjects who have entered the follow -up phase of an investigational study may 
participate as long as it has been [ADDRESS_1126603] allergy to BLD -2660 or inactive components of BLD -2660 . 
5.2. Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical stud y but are not 
subsequently randomized. A minimal set of sc reen failure information is required to ensure 
transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respon d to queries from regulatory 
authorities. Minimal informat ion includes  screening number,  demography, reason for screen 
failure and eligibility criteria.  
Rescreening requests will be on a case -by-case basis and will require Medical Monitor approval . 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 32 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
6. STUDY DRUG  
6.1. Study Drugs  Administered  
For more details on specific indications refer to the BLD -2660 Investigator Brochure (IB).  
Table  3: Study Drug Administered  
 Active  Control  
Drug Name  [CONTACT_813585] -2660  Placebo  
Type  Drug (small mo lecule)  Drug  
Dose Formulation  Capsules, Hard gelatin size ‘00’  Capsules, Hard gelatin size 
‘00’ 
Unit Dose Strength(s)  150 mg  NA 
Dosage Level(s)  900 mg BID (6 capsules BID) for 
a total of 1800 mg per day  NA 
Route of Administration  Oral (PO) ; naso -gastri c tube (NGT) may be used in special 
cases as detailed in Administration instruction below.  
Administration 
instruction  Study drug to be taken orally BID:  
• Morning dose to be taken at least one hour before food  
• Evening dose to be taken at least [ADDRESS_1126604], both active and placebo, will be supplied in bulk 
packaging (40 capsules/bottle). Label text will at a minimum 
include the protocol number, lot number, storage conditions, 
and Sponsor name [CONTACT_3816]. Labels comply with regulatory 
requirements for study drugs.  
 
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126605] of Care  
In both study groups, subjects should receive appropriate supportive care measures as deemed 
necessary by [CONTACT_64372] . 
6.3. Preparation/Handling/Storage/Accountability  
• Drug product will be shipped refrigerated at 2-8°C with a temperature monitor. The 
Investigator  or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study drug received and any discrepancies are 
reported and resolved before use of the study drug. 
• Only subject s enrolled in the study may receive study drug and only authorized site 
staff may supply or administer study drug. All study drugs  must be stored in a secur e, 
refrigerated ( 2-8°C), and monitored (manual or  automated) area in accordance with 
the labeled storage conditions with access limited to the Investigator  and authorized 
site staff.  
• The Investigator , institution, or the head of the medical institution (wh ere applicable) 
is responsible for study drug accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  Clinical supplies  including 
study drug  and inventory records must be made available upon in spection by 
[CONTACT_2728]/FDA upon request. The site mo nitors  will review the records along with 
other study records during monitoring visits . 
• Further guidance and information for the final disposition of unused study drug is 
provided within the  Pharmacy Manual . 
6.4. Measures to Minimize Bias: Randomization and Bli nding  
All subjects will be centrally assigned to randomized study drug using an Interactive Response 
Technology  (IRT). Before the study is initiated, the log in information & directions for the IRT 
will be p rovided to each site.  
Randomization will be strat ified by  [CONTACT_813553] (yes/no )  
Study drug will be dispensed by [CONTACT_813562]/research nurse in 
a blinded manner per the schedule summarized in the SoA (Section  1.2). 
The IRT will be programmed with blind -breaking instructions. Subject safety must always be the 
first consideration in making such a determination. If the Investigator decides that unblinding is 
warranted, the Inv estigator should make every effort to contac t the Sponsor  prior to unblinding a 
subject’s drug assignment unless this could delay emergency treatment of the subject. If a 
subject’s drug assignment is unblinded, the Sponsor  must be notified within [ADDRESS_1126606] be recorded in the source 
documentation and case report form, as applicable.  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126607] but 
not administered should be documented as such  in the source documents and CRF. Deviation(s) 
from the prescribed dosage regimen should be recorded in  the eCRF.  
A record of the number of  BLD -[ADDRESS_1126608] study drug administration will be recorded and reviewed by [CONTACT_3786] (or designee) to determine whe ther the subject is eligible for inclusion.  
Treatment with anot her study drug, investigational device, or approved therapy for 
investigational use within 30 days (or five half -lives, whichever is longer) before anticipated 
dosing is prohibited.  
Allowed med ications  during the study : 
• Remdesivir  
Note, for subjects receiv ing remdesivir therapy, BLD -[ADDRESS_1126609] an hour 
before remdes ivir administration . 
6.6.1.  Prohibited Medications and Herbal Supplements:  
Below is a list of medications that are  prohibited during the study.  
• Anti-IL-6, IL -6 receptor antagonists, or JAKi  
 
6.6.2.  Restricted Medication s 
Restricted medications are defined as medications which should be avoided, if possible; 
however, they are not necessarily prohibited during this study . If such medications are 
require d, consider switching to another medication in the class that is not restricted. If a 
restricted medication is required, seek approval of the Medical Monitor and use with caution per 
approved product label.  
• FDA EUA or compassionate use agent (s) (to be disc ussed with Medical Monitor)  
• Chloroquine, hydroxychloroquine, azithromycin  (Note: prior to prescribing  these 
medications , must seek approval of the Sponsor’s Medical Monitor ) 
• HIV anti -viral drugs  
• H2 blockers and antacids will be allowed as long as they are administered 2 hours 
before or after administration of study drug.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 35 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
BLD -2660 as a Perpetrator  
CYP3A4  
The following are examples of some CYP3A4 substrates  whose e xposure could be reduced due 
to induction of that enzyme ; however, it is not all inclusive and subjects should be monitored for 
adverse effects of these and CYP3A4 substrates in general.  
• HMG CoA reductase inhibitors:  atorvastatin, cervistatin, lovastatin,  and simvastatin.  
Note: Subjects taking the above statins can be switched to any of the following 
medications: pravastatin (Pravachol), rosuvastatin (Crestor), pi[INVESTIGATOR_2830] (Livalo), 
and fluvastatin (Lescol). If subject is unable to switch statin medicatio ns for any 
reason, the investigat or to consult with Sponsor’s Medical Monitor.  
• Benzodiazepi[INVESTIGATOR_1651]  
• Immune modulators  
• Cyclosporine  
• Tacrolimus  
• Calcium channel blockers  
• Hormonal contraceptives  (refer to Section  10.4.2 ) 
CYP1A2  
The following are examples of some CYP1A2 substrates whose exposure could be reduced due 
to induction of that enzyme; however, it is not all inclu sive and subjects should be monitored for 
adverse effects of these and CYP1A2 substrates in g eneral.  
• Non-steroidal anti -inflammatory drugs ( NSAIDs ):  Acetaminophen, phenacetin, 
naproxen  
• Anticoagulants:  Warfarin  
• Antiemetics:  Ondansetron  
• Tricyclic antidepressants:  Clomipramine, doxepin, imipramine  
• Selective serotonin and norepi[INVESTIGATOR_135421] i nhibitors ( SSNRIs ):  Duloxetine, 
fluvoxamine  
• Antipsychotics:  Olanzapi[INVESTIGATOR_050]  
• Bronchodilators:  Theophylline  
• Calcium channel blockers:  Verapamil  
CYP2B6  
The following are examples of some CYP2 B6 substrates whose exposure could be altered due to 
inhibition or in duction of that enzyme; however, it is  not all inclusive and subjects should be 
monitored for adverse effects of these and CYP2B6 substrates in general.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 36 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
• Antidepressants:  Bupropi[INVESTIGATOR_2394], seleg iline 
• Anesthetics and analgesics:  Ketamine, meperidine, propofol, tramadol  
BLD -[ADDRESS_1126610] the potential to increase or decrease exposure to BLD -2660.  
The following are examples of some CYP3A4 i nhibitors; however, it is not all inclusive and 
subjects should be monitored for adverse effects when any CYP3A4 inhibitor is coadministered  
with BLD -2660.  
• Azole antifungals:  Flucon azole, itraconazole, ketoconazole  
• Macrolide antibiotics:  clarithromycin, erythromycin,  
• Quinoline antibiotics:  ciprofloxacin, norfloxacin  
• Proton pump inhibitors:  esomeprazole, omeprazole, pantoprazole  
• Calcium channel blockers:  Verapamil  
• Others:  Grapefr uit juice, starfruit  
The following are examples of some CYP3A4 inducers; h owever, it is not all inclusive and 
subjects should be monitored for adverse effects when any CYP3A4 inducer is coadministered  
with BLD -2660.  
• Barbiturates  
• Anticonvulsants:  Carbamaze pi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_050], phenytoin  
• Rifabutin and rifampin  
• Glucocorticoids  
• St. John’s Wort  
Transporter Interactants  
The following are examples of some P -glycoprotein  inhibitors; however, it is not all inclusive 
and subjects should be monitored for adverse effects when any P -glycoprotein  inhibitor is 
coadministered  with BLD -2660.  
• amio darone, carvedilol, clarithromycin, dronedarone, itraconazole, lapatinib, 
lopi[INVESTIGATOR_55344] d ritonavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir and 
ritonavir, telaprevir, tipranavir and ritonavir, verapamil  
The following are examples of some breast cancer resistance protein ( BCRP ) inhibitors; 
however, it is not all inclusive an d subjects should be monitored for adverse effects when any 
BCRP inhibitor is coadministered  with BLD -2660.  
• curcumin, cyclosporine A, elt hrombopag   
 
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126611] should receive treatment directed towards any symptoms manifested.  
In the event of an overdose, the Investigator should:  
1. Contact [CONTACT_192142].  
2. Closely monitor the subject for any AE/SAE and laboratory abnormaliti es. 
3. Document the quantity of the excess dose as well as the duration of the 
overdose.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_484594]  
6.9. Intervention after the End of the Study  
No additional intervention is planned beyond the end of the study.  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126612]  
DISCONTINUATION/WITHDRAWAL  
7.1. Stoppi[INVESTIGATOR_813522] -19, there are no pre -specified stoppi[INVESTIGATOR_813523] 
a whole . Instead there will be close oversig ht by [CONTACT_813563]  9.5.[ADDRESS_1126613] permanently discontinue study drug  if she becomes pregnant.  See Appendix  4 
(Section  10.4) and Section  8.3.5  for additional details.  
See the SoA ( Section  1.2) for data to be collected at the time of study drug  discontinuation and 
follow -up, and for any further evaluations that need to be completed.  
7.2. Discontinuation of Study Drug  
In some  instances, it may be necessary for a subject  to permanently discon tinue study drug. 
Please also refer to stoppi[INVESTIGATOR_9228]  7.1. 
Permanent discontinuation of study drug does not mean withdrawal from the study, and the 
subject will be encouraged to remain in the  study and continue to complete all study visits . See 
the S oA (Section  1.2) for data to be collected at the time of drug discontinuation and follow -up 
and for any further evaluations that need to be completed.  
Subjects may discontinue or be discontinued from study drug at any time. A subject may 
discontinue study drug for reasons including but not limited to:  
• Adverse event  
• Death  
• Lost to follow -up 
• Non-compliance with study drug  
• Physician decision  
• Pregnancy  
• Lack of  efficacy  
• Protocol deviation  
• Study terminated by [CONTACT_2728]  
• Withdrawal by [CONTACT_1130] * (*only for discontinuing  study drug , but will remain in study ) 
The reason for subject  discontinuation from study drug will be recorded in the eCRF.  At the time 
of treatment com pletion or study drug discontinuation, the EOT/ET visit should be completed as 
shown in the SoA ( Section  1.2). Subjects should continue to be followed for safety even if they 
discontinue study drug  prematurely u nless they withdraw consent.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 39 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Pregnancy is a mandatory criteri on for permanent discontinua tion of study drug  (see 
Section  7.1.1 ). 
7.3. Withdrawal from the Study  
Subjects  have the right to withdraw from the study at any  time and for any reason without 
prejudice to their future medical care by [CONTACT_122697]. A subject may 
withdraw from the study for reasons including but not limited to : 
• Death  
• Withdrawal by [CONTACT_1130]  
• Lost to follow -up 
• Study terminate d by [CONTACT_813564].  
At the time of withdrawal from the study, the end of study visit should be completed , as shown 
in the SoA  (Section  1.2). 
If the subject  withdraws consent for disclosure of future information, the Sponsor  may retain and 
continue to use any data collected before such a withdrawal of consent.  
If a subject  withdraws from the study, he/she may request destruction of any s amples taken and 
not tested, and the Investigator  must document this in the site study rec ords.  
7.4. Lost to Follow up 
A subject  will be considered lost to follow -up if he or she repeatedly fails to return  to the study 
site or be contact[CONTACT_813565] d outpatient visits post hospi[INVESTIGATOR_2345].  
The following actions must be taken if a subject fails to return to the clinic  and/or be available 
for remote contact  [INVESTIGATOR_8178] a required study visit:  
• The site must attempt to contact [CONTACT_79969] m issed visit as soon as 
possible and counsel the subject  on the importance of maintaining t he assigned visit 
schedule and ascertain whether or not the subject  wishes to and/or should continue in 
the study.  
• Before a subject  is deemed lost to follow up, the Investigator  or designee must make 
every effort to regain contact [CONTACT_1155]  (where p ossible, [ADDRESS_1126614] ’s last known mailing address or local 
equivalent methods). These contact [CONTACT_399796] ’s 
medical record.  
• Should the subject  continue to be unreac hable, he/she will be considered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1  
(Section 10.1.8 ). 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 40 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
8. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA  (Section  1.2). Protocol  
waivers or exemptions are not allowed.  
• Immediate safety concerns should be discusse d with the Sponsor  immediately upon 
occurrence or awareness to determine if the subject  should continue or discontinue 
study drug . 
• Adhere nce to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct . 
• All screening evaluations must be completed and reviewed to confirm that potential 
subject s meet all eligibility criteria. The Investig ator will maintain screening 
information  including  details of all subject s screened and to confirm eligibility or 
recor d reasons for screening failure, as applicable.  
• Missed visits should be avoided if at all possible; if a visit is missed  and cannot be 
rescheduled, the subject should resume their original visit schedule at the next 
scheduled visit. In case of natural disa sters or pandemics, some visits/study 
procedures can be done via virtual visits or at home visits when discharged. Refer  to 
study reference manual for more details.  
8.1. Efficacy Assessments  
8.1.1.  Oxygenation Measures  
Peripheral capi[INVESTIGATOR_19365] (SpO 2) with pulse oximeter will be used as surrogate for 
arterial blo od oxygen saturation . While hospi[INVESTIGATOR_057], the SpO 2 will be measured twice a day  
(morning and night) . Measurement is to be done with the subject laying  supi[INVESTIGATOR_813524] , unless indicated otherwise; the same position should be used  throughout the 
study  and the  subject ’s position will be  captured in the eCRF.  The FiO 2 at the time o f each SpO 2 
measurement  (morning and night while hospi[INVESTIGATOR_057])  must also be recorded in the eCRF.  
Peripheral h emoglobin oxygen saturation to inspi[INVESTIGATOR_572355] n fraction (SpO 2/FiO 2) will also be 
measured. Oxygenation will be assessed using the categories in Table  4. 
Table  4: A 4-Point Oxygen Ordinal Scale for  Severity Categories by [CONTACT_7535] 2/FiO 2 Ratio  
Score Severity  SpO 2/FiO 2 (mmHg)  
0 None  > 315  
1 Mild  > 235 to 315  
2 Moderate  > 150 to 235  
3 Severe  ≤ 150  
8.1.2.  Measure of Clinical Support  
At each study day while hospi[INVESTIGATOR_057], the following measure of clinical support should be 
assessed:  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 41 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
• Oxygen requirement  
• Non-invasive mechanical ventilation (via mask)  
• Mechanical ventilator requirement (via endotracheal tube or tracheostomy tube) or 
Extracorporeal membrane oxygenation ( ECMO ) requirement  
• Level of consciousness: alert vs. (arousable only to voice or pain or unre sponsive)  
In addition, date of hospi[INVESTIGATOR_813525] (if different) will be 
collected.  
8.1.3.  Clinical Status Ordinal  Score  
Clinical status will be asse ssed using the 6-point ordinal score ( Table 5). The ordinal scale is an 
assessment of the clinical status at the first assessment of a given study day. Each day, the worse 
score for the previous day will be recorded. i.e. on  day 3, day 2 score is obtained and recorded as 
day 2. This scale has been used successfully as an endpoint for evaluat ion of  treatments for 
severe influenza requiring hospi[INVESTIGATOR_12191] ( Peterson, 2017 ). 
Table 5: A 6-Point Ordinal Score for Assessing Clinical Status  
Score  Description  
1 Not hospi[INVESTIGATOR_057]  
2 Hospi[INVESTIGATOR_057], not requiring supplemental oxygen  
3 Hospi[INVESTIGATOR_057], requiring supplemental oxygen  
4 Hospi[INVESTIGATOR_057], on non -invasive ventilation or high flow o xygen devices  
5 Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO  
6 Death  
8.1.4.  National  Early Warning Score (NEWS)  
The NEWS has demonstrated an ability to discriminate subjects at risk of poor outcomes. ( Smith, 
2016 ; Williams, 2019 ). This score is based on 7 clinical parameters, vital signs (respi[INVESTIGATOR_697], 
temperature, blood pressure, and heart rate), SpO2, breathing room air or supplemental oxygen, 
and consciousness ( Table  6). The NEWS is being used as an efficacy measure.  
NEWS will be derived from other parameters to be collected during the study as specified in 
SoA (Section  1.2). 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 42 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Table  6: NEW Score  
 
Level of consciousness: alert (A), arousable only to voice (V), or pain (P) and unresponsive (U)  
8.1.5.  Hospi[INVESTIGATOR_813526]’s readiness for hospi[INVESTIGATOR_813527] 
(must meet all):  
• Normal O 2 saturation on room air  or a return to pre -morbid status  
• Afebrile  
• Able to ambulate (or use commode) with out assistance or a return to  pre-morbid 
mobility (for non -ambulatory subjects)  
• Able to dress self or a return to pre -morbid status  
• Eating pre -morbid full diet or a return to pre -morbid status  
Date of actual hospi[INVESTIGATOR_813528] d uring the study period should  be 
captured.  Subjects ’ oxygen supplementation status at hospi[INVESTIGATOR_813529]  
(with vs. without oxygen supplementation) . 
8.1.6.  Antiviral Activity  
Quantitative viral load using nasopharyngeal swab /sputum  SARS -CoV -2 PCR will be used to 
monitor disease status during the study. For more details refer to the laboratory manual.  
 

 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 43 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA  (Section  1.2). 
8.2.1.  Physical Examinations  
• Physical examinations will be performed by [CONTACT_813566], a designated 
sub-investigator  or a qualified hospi[INVESTIGATOR_813530].  
• A complete physical examination will include, at a minimum, assessments of the 
skin, cardiovascular  system , respi[INVESTIGATOR_36517] , abdomen ( gastrointestinal , liver and 
spleen)  and neurological  system. Height and wei ght will also be measured and 
recorded.  
• A symptom -directed physical examination will include, at a minimum, assessments of 
the skin, respi[INVESTIGATOR_36517] , cardiovascular system, and abdomen (liver and spleen) . 
8.2.2.  Vital Signs  
• Blood pressure, heart rate, and respi[INVESTIGATOR_813531] 5 minutes.  
• Temperature will be recorded twice daily while  hospi[INVESTIGATOR_057]  (morning and evening)  
• Vital signs will be measured prior to any blood draw that occurs at the same 
timepoint  
8.2.3.  Electrocardiograms  
12-lead ECG will be obtained while subject is in supi[INVESTIGATOR_813532] s the heart rate and measures PR, QRS, and QT (QTcF), intervals. Subject 
to be resting for at least 2 minutes prior to ECG.  
8.2.4.  Clinical Safety Laboratory Assessments  
• See Appendix 2  (Section  10.2) for the list of clinical laboratory tests to be performed 
and to the SoA for the timing and frequency.  
• The Investigator  must review the laboratory report, document this review, and record 
any clinically significant adverse changes occurring during the study in the AE 
section of the eCRF. The laboratory reports must be filed with the source documents.  
• All laboratory tests with values considered clinically significantly during participation 
in the study or within  [ADDRESS_1126615] dose of study drug should be repeated 
until the values return to normal or baseline or are no longer considered clinically 
significant by [CONTACT_813567] r’s Medical Monitor/designee . 
− If such clinically significant values do not return to normal/baseline within  a 
period of time judged reasonable by [CONTACT_737] , the etiology should be 
identified,  and the Sponsor  notified.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 44 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
− All protocol -required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the  SoA.  
− If laboratory values from non -protocol specified laboratory assessments 
performed at the institution’s local laboratory require a change in subject  
management or are considered clin ically significant by [CONTACT_737]  (e.g., SAE 
or AE or dose modif ication), then the results must be recorded in the eCRF.  
8.3. Adverse Events and Serious Adverse Events  
The definitions of an AE and SAE can be found in Appendix 3 (Section  10.3). 
All AEs will be reported by [CONTACT_46897] (or, when appropriate, by a caregiver, surrogate, or the 
subject's legally authorized representative).  
The Investigator  and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of AE, SAE . 
All AEs will be classified for severity using the common terminology criteria for AEs (CTCAE) 
V.5. 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
Table 7 below summarizes the different reporting peri ods for AEs and SAEs.  
Table 7: Adverse Event Reporting Periods  
Type of Event  Adverse Event  Serious Adverse Event  
Reporting period  From consent until Day 28 visit (at 
least [ADDRESS_1126616] dose of study 
drug). From consent until Day 28 visit (at least 
[ADDRESS_1126617] dose of study drug ). 
SAEs will be recorded for study drug 
and for remdesivir.  
Reporting Timelines 
to the Sponsor   Entered into the clinical database 
on an ongoing basis   Within 24 hours of site awareness  
Medi cal occurrences that begin before the start of study drug but after obtaining informed 
consent will be recorded on the Adverse Events  section of the case report form (CRF) and will 
be identified in the analysis as non -treatment -emergent adverse events (non-TEAEs) . 
All SAEs (for study drug and for remdesi vir) will be recorded and reported to the Sponsor  or 
designee immediately and under no circumstance should this exceed  24 hours  from site 
awareness , as indicated in Appendix 3 (Section  10.3). The Investigator will submit any updated 
SAE data to the Sponsor  or designee within [ADDRESS_1126618] has been discharged from the study, and he/she considers the event to be related to the 
study drug or study participation, the I nvestigator must promptly notify the Sponsor  or designee . 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 45 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
8.3.2.  Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE s and SAE s and the 
procedures for completing and transmitting SAE reports are provided in Appendix 10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading  verbal questioning of the subject  is the preferred method to inquire about 
AE occurrences.  
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE  report, the Investigator  is required to proactively follow each subject  at 
subsequent visits/contacts. All SAEs,  will be followed until resolution, stabilization, the event is 
otherwise explained, or the subject  is lost to follow -up (as defined in Section  7.4). Further 
information on follow -up procedures is provided in Appendix 10.3. 
8.3.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by [CONTACT_208022] a SAE is essential so that 
legal obligations and ethical responsibilities towards the saf ety of subject s and the 
safety of a study drug under clinical investigation are met.  
• The Sponsor  has a legal responsibility to notify both the local regulatory authority 
and other regulatory age ncies about the safety of a study drug under clinical 
investig ation. The Sponsor  will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Commit tees (IEC) , and Investigator s. 
• For all studies must be prepare d for suspected unexpected serious adverse reactions 
(S[LOCATION_003]R) according to local regulatory requirements and Sponsor  policy and 
forwarded to Investigator s as necessary.  
• An Investigator  who receiv es an Investigator  safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the Sponsor  will 
review and then file it along with the  IB and will notify the IRB/IEC, if appropriate 
according to local require ments.  
8.3.5.  Pregnancy  
• Details of all pregnancies in female subject s and  of female partners of male subject s 
will be collected as outlined in Section  10.4 (Appendix 4) . 
• If a pregnancy is reported, the Investigator  shou ld inform the Sponsor  within 24 hours  
of learning of the pregnancy and should follow the procedures outlined in 
Appendix  4. 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
conge nital anomalies, ectopic pregnancy) are consi dered SAEs.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 46 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
8.3.6.  Deaths  
All deaths will be recorded in  the eCRF.  As deaths are always considered SAEs, they should be 
reported to the Sponsor within 24 hours of site awareness.  
8.4. Pharmacokinetics  
PK assessment of BLD -2660 will be analyzed using a population PK ap proach based upon 
sparse sampling to be obtain at designated timepoints as specified in the SoA ( Section  1.2). Note, 
if NGT is inserted, PK samples will also be collected [ADDRESS_1126619] NGT use . 
• Instructions for the collection and handling of biological samples will be provided by 
[CONTACT_1034]. The actual date and tim e (24 -hour clock time) of each sample will be 
recorded.  
• Samples will be used to evaluate the PK of BLD -2660 . Samples collected for 
analyses of BLD -2660  serum concentration may also be used to evaluate safety, 
efficacy and/or pharmacodynamic aspects related  to concerns or questions arising 
during or after the study.  
• Subject confidentiality will be maintained. At visits during which blo od samples for 
the determination of PK, and PD related to BLD -2660  will be taken, 1  sample of 
sufficient volume can be used.  
• Any changes in the timing or addition of time points for any planned study 
assessments must be documented and approved by [CONTACT_813568] a protocol 
amendment. The  IRB/IEC will be informed of any safety issues that require alteration 
of the safety monitoring scheme or amendment of the ICF.  
8.5. Pharmacodynamics  and Biomarker Assessments  
Blood samples will be collected and analyzed  for biomarker analysis as specified in the SoA 
(Section  1.2) including IL-[ADDRESS_1126620]’s last visit for the study, 
at a facility selected by [CONTACT_1034] , to enable further analysis of biomarker responses to 
BLD2660 . 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 47 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
9. STATISTICAL CONSIDERATION S 
9.1. Statis tical Hypothesis  
Two primary hypotheses will be tested. The study  will be declared a success if either of the 
hypotheses are statistically significant.  
Hypothesis 1: Will evaluate clinical benefit in hospi[INVESTIGATOR_813533] -
CoV -[ADDRESS_1126621] 
ratio is = [ADDRESS_1126622] ratio does not equal 1. 
Hypothesis 2: Will evaluate improvement in oxygenation in hospi[INVESTIGATOR_813534] -CoV -2 infection at the time of discharge, or Day 10, if they are still hos pi[INVESTIGATOR_057]. 
The primary endp oint is the change from baseline to Day 10 or hospi[INVESTIGATOR_813535] (SpO 2/FiO 2). The null 
hypothesis is the mean treatment difference equals [ADDRESS_1126623] bo-control study  evaluating remdesivi r in 1063 hospi[INVESTIGATOR_139096] -19 reported 606 recoveries, with a median time to recovery of 11 days and 
15 days in the remdesivir and placebo groups, respectively  (remdesivir package insert) .  
Recovery was defined as the f irst day on which the  subject satisfies one of the following 3 
categories from the ordinal scale: 1) Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer 
requires ongoing medical care; 2) Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring h ome 
oxygen; 3) Not ho spi[INVESTIGATOR_057], no limitations on activities  
(https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED] ). 
Assuming the median time to clinical improvement, defined as no longer requirin g oxygen 
support or hospi[INVESTIGATOR_813536] , will be [ADDRESS_1126624] 80% power to detect a 50% reduction in the tim e to clinical 
improvement, (i.e., hazard ratio of 0.5).  
Change from baseline to Day 10 or hospi[INVESTIGATOR_813537] (SpO 2/FiO 2). 
A prospective observational co hort study of non -intubated moderate to severe ARDS patients 
(Ding, 2020 ) reported the partial pressure of oxygen (PaO 2)/FiO [ADDRESS_1126625] devia tion of 147 ± 46 mm Hg. Converting to a Sp0 2/FiO [ADDRESS_1126626] deviation of 192 ± 39 using the equation reported by [CONTACT_813569]. (2007)  (Rice, 
2007). 
Assuming a standard deviation of 40 in the SpO2/FiO 2 ratio, a sample size of 120 subjects (80 
active, vs 40 control) will provide approximately 90% power to detect a treatment difference in 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 48 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
the SpO2/FiO [ADDRESS_1126627] with a two -sided 5% 
significance level  
9.3. Population Analysis Set  
For purposes of analysis, the following populations are defined:  
Population  Description  
Full Analysis 
Set (FAS)  All randomized subjects who receive at least one dose of study drug. This 
population will be used for all efficacy ana lyses 
Modified Intent 
to Treat  (MITT ) All randomized subjects who receive at least one dose of study drug and 
one post baseline assessment of the SpO2/FiO 2 ratio. This population will 
be used fo r the primary and secondary endpoints relat ed to improvement 
in SpO2/FiO [ADDRESS_1126628] plasma 
concentration data  
9.4. Statistical Meth ods 
Detailed methodology for summary and statistical analyses of the data collected in this study will 
be documented in a statistical analysis plan (SAP), whic h will be maintained by [CONTACT_1034]. The 
SAP may modif y the plans outlined in the protocol; howev er, any major modifications will also 
be reflected in a protocol amendment. This section is a summary of the planned statistical 
analyses of the primary and se condary endpoints . 
9.4.1.  General  
In general, summary tabulat ions will be presented that display the num ber of observations, mean, 
standard deviation, median, minimum, and maximum for continuous variables, and the number 
and percent (of non -missing values) per ca tegory for categorical data . 
9.4.2.  Efficacy Analyses  
The pri mary efficacy endpoint of time to clinical improvement will be presented using the 
Kaplan -Meier estimator . Subjects  will be censored at Day 2 8 or earlier, if  they discontinue the 
study prior to observing the event.   A Cox proportional hazards model with tr eatment, remdesivir 
use (yes/no) and age as  covariates will be used to estimate the hazard ratio and compare 
treatment groups.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 49 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
The primary efficacy endpoint of change from baseline to Day 10 or hospi[INVESTIGATOR_36514], 
in the ratio of hemoglobin oxygen saturation to inspi[INVESTIGATOR_619039] ( SpO 2/FiO 2) will be 
analyzed a mixed measure s repeated  model  (MMRM). The Kenward -Roger method will be used 
to calculate the denominator degrees of freedom for the test of fixed effects  and adjusted 
standard errors . The model will contain  treatment , time and  the treatment by [CONTACT_813570], age, and remdesivir  drug use (yes vs no)  as covariates . An 
unstructured covariance matri x will be assumed  to model the within -participant errors .  
Sub-group analyses for the two primary endpoints will also be conducted for the followin g sub -
groups: Chloroquine or hydroxychloroq uine use (yes vs no) , HIV anti -viral drug use (yes vs no)  
and azithromycin use (yes vs no) . If warranted, these effects may be included in the primary 
model.  
No adjustment for multiplicity among the two primary en dpoints will be made, as this is a 
Phase 2 study. Secondary endpoints will be analyzed without adjustment for multiplicity . All 
efficacy analyses will use  the FAS analysis set, and MITT  analysis set if applicable.  
Secondary endpoints that are defined as time to event endpoints will  be analyzed using survival 
analysis methods. Data will be presented using the Kaplan -Meier . Subjects will be censored at 
Day 28 or earlier, if they discontinue the study prior to observing the event.  A Cox proportional 
hazards model with treatment, remdesivir use ( yes/no), and age as covariates will be used to 
estimate the hazard ratio and compare treatment groups.  
Secondary endpoints that are defined as proportions will be summarized using frequency counts 
and proportions.  Treatment groups will be compared using a Cochran–Mantel –Haenszel  (CMH ) 
test stratified by [CONTACT_813571] (yes vs no). Additional covariates  may be included if warranted.  
Change from baseline in SARS -CoV -2 viral load at Day 10 /EOT  (or hospi[INVESTIGATOR_2345], 
whichever is sooner and end of study (Day 28) will be analyzed using an MMRM  model . 
The propor tion of patients reporting each of the cate gories using the 6-point ordinal scale will be 
compared between treatment groups using the CMH test . 
The change from baseline in the NEWS score will be summarized at each time point . A 
comparison between treatment groups will be made using a n MMRM  model .  
The following secondary endpoints: number of O 2 supplementation free days, change from 
baseline in clinical status using 6-point  ordinal scale ( Table 5), and improvement (i.e., change) 
from baseline  as measured by [CONTACT_813572][INVESTIGATOR_813538] (SpO 2/FiO 2) using the 4 -point ordinal scale ( Table  4) will be summarized using 
descrip tive statistics and comparisons between tre atment groups made using appropriate 
statistical methods . 
The mean SpO [ADDRESS_1126629] current Medica l Dictionary for Regulatory Activities  (MedDRA®). The number of subjects 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 50 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
experiencing TEAEs) and number of individual TEAEs will be summariz ed by [CONTACT_3148], system 
organ class and preferred term. TEAEs will also be summarized by [CONTACT_813573] p 
to study drug. Serious TEAEs (SAEs) and TEAEs leading to discontinuation of study drug will 
be summarized by [CONTACT_3148], system organ class  and preferred term.  
Laboratory evaluations, vital signs assessments and ECG parameters will be summarized by 
[CONTACT_813574].  
9.4.4.  Other Analyses  
BLD -[ADDRESS_1126630] ics. 
Pharmacokinetic parameters will be estimated using a population PK approach . 
Change from baseline in IL6 and D -dimer will be analyzed using a repeated measure mixed 
effects model. Missing data will be assumed  to be missing at random. The model will in clude 
fixed effects for treatment group, and remdesivir use (yes vs no). Additiona l covariates may be 
included if warranted. Subjects will be treated as random, wi th an unstructured covariance 
structure. The least square (LS) means, and 95% confidence intervals within treatment and for 
the tre atment difference will be reported at each timepoint.  
9.5. Interim Analysis  
Interim analyses are planned when appr oximately 25%, 50% and 75% of subjects have 
completed the study for the purpose of early stoppi[INVESTIGATOR_582413].  The tim ing of these 
interim analyses may change ba sed on the rate of recruitment.  If recruitment is extremely quick 
these interim an alyses  may not be conducted.  
The Lan -DeMets spending function analog of the O’Brien -Fleming boundaries will be used to 
monitor each of the primary endpoint s as a guide for th e DMC for an overall two -sided type -I 
error rate of 5%, for each endpoint . 
Conditi onal power will be used as an additional guide to the DMC  to assess futility . Conditional 
power allows computation of the probabili ty of obtaining a statistically significant  result by [CONTACT_813575]. If the conditional power is less than 20% 
under the original study  assumptions, consideration should be given to stoppi[INVESTIGATOR_10098] . 
At the inte rim analysis when approximately 50% of the subjects have completed the study , a 
sample size re -estimation step will occ ur using the promising zone approach and method of 
Chen, DeMets and Lan, based on the observed effect size at this interim analysis.  The promising 
zone is defined as a conditional power of between 50% and 90%. If the conditional power falls into 
this regio n the sample size may be increased.  Further statistical details surrounding the interim 
analysis, including the stoppi[INVESTIGATOR_74239], will  be included in the statistical analysis pl an. 
The study will not stop enrolment awaiting these DMC reviews, though the  DMC may 
recommend temporary or permanent cessation of enrolment based on their safety reviews.  
A separate unblinded statistical team wil l prepare the above information for the DMC  to review 
and make recommendations to the Sponsor . 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 51 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
9.5.1.  Data Monitoring Committee  
The DMC, a specific independent committee for the study with external representation, will mee t 
when approximately 25%, 50% and 75% of subjects have been recruited and on an ad h oc basis 
to review safety results. The DMC may recommend stoppi[INVESTIGATOR_813539]. The members of th e DMC will be listed in 
a separate DMC Ch arter, the governing document that will sup ersede this section of the protocol.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 52 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study wil l be conducted in accordance with the proto col and with the following:  
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) Internat ional Ethical Guidelines  
− Applicable ICH Goo d Clinical Practice (GCP) Guidelines  
− Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigator  Brochure, and other relevant 
documents (e.g., adve rtisements) must be submitted to an IRB/I EC by [CONTACT_813576]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate  an immediate hazard to study subject s. 
• The Investigator  will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with th e requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
− Notifying the IR B/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
− Providing oversight of the conduct of the study at the site and adherence to 
requiremen ts of 21 CFR, ICH guidelines, the IRB/IEC , European regulation 
536/2014 for clinical  studies (if applicable), and all other applicable local 
regulations  
10.1.2.  Financial Disclosure  
Investigators and sub -investigators will provide the Sponsor  with sufficient, accu rate financial 
information as requested t o allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study an d for 
1 year after completion of the study.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 53 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.1.3.  Informed Consent Process  
• The Investigator or his/her representative will explain the nature of the study to the 
subject  or his/her legally authorized representative and answer all questions regarding 
the study.  
• Subject s must be inf ormed that their partici pation is voluntary. Subject s will be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_1126631] (HIPAA) requirem ents, where applicable, and the IRB/IEC or 
study center.  
• The medical record must include a statement that written informed consent was 
obtained before any study -specific procedures were performed and the date the 
written consent was obta ined. The authorize d person obtaining the i nformed consent 
must also sign the ICF.  
• Subject s must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the  signed  ICF(s) must be provided to the subject  or the subject ’s legally 
authorized represe ntative. 
•  Subject s who are rescreened are required to sign a new ICF.  
The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for optio nal exploratory research. The investigat or or authorized designee will explain to e ach 
subject  the objectives of the exploratory research. Subject s will be told that they are free to 
refuse to participate and may withdraw their consent at any time and for any reason during the 
storage period. A separate signature [CONTACT_813586] a subject 's agreement to allow 
any remaining specimens to be used for exploratory research. Subject s who decline to participate 
in this optional research will not provi de this separate signature.  
10.1.4.  Data Protect ion 
• Subject s will be assigned a unique iden tifier by [CONTACT_1034] . Any subject  records or 
datasets that are transferred to the Sponsor  will contain the identifier only; subject  
names or any information which would mak e the subject  identifiable will not be 
transferred.  
• The subject  must be informed th at his/her medical records may be examined by 
[CONTACT_13162] , by [CONTACT_6667]/IEC members, and  by [CONTACT_813577]. 
10.1.5.  Dissemination of Clinical Study Data  
A clinical study report will be developed by [CONTACT_813578]. This 
report will be a clinical and statistical integrated report, according to the ICH  E3 guidelines.  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126632] study results regardless o f outcome on a publicly 
accessible website in accordance with the applicable laws and regulations . 
10.1.6.  Data Quality Assurance  
• All subject  data relating to the study will be recorded on printed or electronic CRF 
unless  transmitted to the Sponsor  or designee ele ctronically (e.g., laboratory data). 
The Investigator is responsible for verifying that data entries are accurate and correct 
by [CONTACT_139136].  
• The Investigator must maintain accurat e documentation (source data) that supports  
the information entered in the CRF.  
• The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory ag ency inspections and provide direct access to source data documents.  
• Monitoring details describing strategy (e.g., risk -based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical Risk -
Based Monitoring), met hods, responsibilities and requirements, including handling of 
noncompliance iss ues and monitoring techniques (central, rem ote, or on -site 
monitoring) are provided in the Clinical Monitoring Plan.  Due to the infectious nature 
of COVID -19, the Sponsor (or d esignees) will work with clinical sites to implement 
remote monitoring procedure s with a focus on review  and source data ve rification 
(SDV) of safety data.  
• The Sponsor  or designee is responsible for the data management of this study 
including quality check ing of the data.  
• The Sponsor  assumes accountability for actions delegated to oth er individuals (e.g., 
Contract Research Org anizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_813579] -GCP and local regulations or 
institutional policies . No records may b e destroyed during the retention period 
without the written approval of the Sponsor . No records may be transferred to another 
location or party without written notification to the Sponsor . 
10.1.7.  Source Documents  
• Source documents provide evidence for the existenc e of the subject  and substantiate 
the integ rity of the data collected. Source documents are filed at the Investigator ’s 
site. 
• Data reported on the CRF or entered in the eCRF th at are transcribed from source 
documents must be consistent with the source docu ments or the discrepancies must be 
explaine d. The Investigator  may need to request previous medical records or transfer 
records, depending on the study. Also, current medical r ecords must be available.  
• Source documents are original documents, data, and rec ords from which the subject ’s 
eCRF data are  obtained. These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126633] been collected and a study -site closure visit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable caus e 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_14345]:  
• Failure of the Investigator  to comply with the protocol, the requireme nts of the 
IRB/IEC or local health authorities, the Sponsor 's procedures, or GCP guidelines  
• Inadequate recruitment of subject s by [CONTACT_737]  
• Discontinuation of further study drug development  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigator s, the IECs/IRBs, the regulato ry authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_3433] e 
applicable regulatory requirements. The Investigator  shall promptly inform the subject and 
should assure appropriat e subject therapy and/or follow -up. 
10.1.9.  Publication Policy  
• The results of this study may be published or presented at scientific meetings. If t his 
is foreseen, the Investigator  agrees to  submit all manuscripts or abstracts to the 
Sponsor  before submission. Thi s allows the Sponsor  to protect proprietary 
information and to provide comments.  
• The Sponsor  will comply with the requirements for publicat ion of study results. In 
accordance with st andard editorial and ethical practice, the Sponsor  will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating Investigator  [INVESTIGATOR_1318] b e designated by [CONTACT_231692].  
• Authorshi p will be determined by [CONTACT_14346].  
  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 56 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.2. Appendix 2: Clinical Laboratory Tests  
• The clinical laboratory tests detailed in Table  8 will be performed by a local  
laboratory , except where specified below,  at the timing/frequency detailed in the SoA.  
• Protocol -specific requirements for inclusion or exclusion of subjects are detailed in 
Section  5 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_9332]  
• Investigators must document thei r review of each laboratory safety report.  
Table  8: Protocol -Required Laboratory Assessments  
Hematology   
White blood cell count (WBC) with absolute 
differential (Neutrophils, Lymphocytes, 
Monocytes, Eosinophils, Basophils)  Red blo od cell (RBC) with indices (mean 
corpuscula r volume [MCV] and mean corpuscular 
hemoglobin [MCH])  
Hemoglobin  Hematocrit  
Platelet count   
Clinical Chemistries  
Alanine aminotransferase  (ALT)  Aspartate aminotransferase ( AST)  
Alkaline phosphatase  Gamma -glutamyl transferase (GGT)  
Total and direct bi lirubin (fractionated)  Blood urea nitrogen (BUN)  
Albumin  L-lactate dehydrogenase (LDH)  
Calcium  Creatinine  
Sodium  Potassium  
Glucose  Total protein  
Chloride  Bicarbonate  
Urinalysis  
Basic Urinalysis (dipstick, i ncluding macroscopic  appearance, bilirubin,  blood, color, glucose,  
ketones, leukocyte esterase, nitrite, pH, protein,  specific gravity, urobilinogen)  
Other Laboratory Assessments  
• Troponin  (serum)  
• IL-6 (to be analyzed at central laboratory)  
• D-dimer  
• Coagul ation panel: International normalized ratio  (INR) 
• Serum ferritin  
• Serum high sensitivity C-reactive protein ( hsCRP)  
• Serum pregnancy tes t 
• SARS -COV -2 (COVID -19) test ( RT-PCR via nasopharyngeal swab)  
  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 57 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.3. Appendix 3: Adverse Events: Definitions and Procedures fo r 
Recording, Evaluating, Follow -up, and Rep orting 
10.3.1.  Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study subject , 
temporally associated with the use of study drug, whether or not considered related 
to the st udy drug. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (includ ing an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study drug. 
 
Events Meeting  the AE Definition  
• Any abnorm al laboratory test results (hematology, cli nical chemistry, or urinalysis) 
or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline  (see bullet below) , 
considered clinically significan t in the medical and scientific judgment of  the 
Investigator  (i.e., not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condit ion. 
• New conditions detected or diagnosed a fter study drug administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symp toms, or the clinical s equelae of a suspected overdose of either s tudy 
drug or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses  should be reported reg ardless of sequelae.  
 
Events NOT  Meeting t he AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_738822] ’s condition.  
• The disease/disord er being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
subject ’s condition.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 58 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
• Medical or surgical procedure (e. g., endoscopy, appendectomy): the condition  that 
leads to the  procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing dis ease(s) or condition(s) 
present or detected  at the start of t he study that do not worsen.  
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospi[INVESTIGATOR_1080]/symptom s of the disease under study, death due to 
progression of dis ease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
Results in death  
Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject  
was at risk of death a t the time of the event. It does not refer to an event which hypothetically 
might have caused death, if it were more severe.  
Requires inpatient hospi[INVESTIGATOR_1081]  
• In gener al, hospi[INVESTIGATOR_5184] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment  that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in  doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred or was necessary, the AE shoul d be considered serious.  
• Hospi[INVESTIGATOR_1086] r elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
Results in persistent disa bility/incapacity  
• The term disability means a substantial disruption of a pers on’s ability to conduct 
normal life functio ns. 
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nau sea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankl e) which may interfere with or 
prevent ever yday life functions but do not constitute a substantial disruption.  
Is a congenital anomaly/birth defect  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 59 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as imp ortant medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_126689] t he subject  or may require medical or surgical drug to prevent one 
of the other outcomes listed in the above definition. These event s should usually be 
considered serious.  
• Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic broncho spasm, blood dyscrasias or 
convulsions  that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency or drug abuse.  
 
10.3.3.  Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all 
documentation (e.g.,  hospi[INVESTIGATOR_1088], laboratory report s, and diagnostics 
reports) related to the event.  
• The Investigator  will then record all relevant AE/SAE informa tion in the CRF.  
• It is not acceptable for the Investigator  to send photocopi[INVESTIGATOR_9238] ’s medica l 
records to  the Sponsor or designee in lie u of completion of the AE/SAE CRF page.  
• There may be instances when copi[INVESTIGATOR_813540].  In this case, all subject  identifiers, with the 
exception o f the subject  number, will be redacted on t he copi[INVESTIGATOR_813541] . 
• The Investigator  will attempt to  establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whene ver possible, the diagnosis (not 
the indivi dual signs/symptoms) will be documented as the AE/SAE.  
 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 60 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Assessment of Severity  
AE severity will be evaluated by [CONTACT_813580] v5.  0 1. 
For AEs that are not adequately addresse d in the NCI CTCAE, the Investigator  should  classify 
the intensity of the AE using the following guidelines:  
Grade 1:  Mild:  Aware of sign or symptom, but easily tolerated; no intervention  needed  
Grade 2:  Moderate:  Discomfort enough to cause interferenc e with usual activity, minimal 
non-invasive  intervention indicated (e.g., short course of antibiotics)  
Grade 3:  Severe:  Medically significant but not immediately life -threatening; 
incapacitation with inability to work or do usual activity  
Grade 4:  Life -threatening:  Refers to an event in which t he subject  was at risk of death at 
the time of the event, as judge d by [CONTACT_737] ; urgent/emergent drug indicated. 
This category should not be used for an event that hypothetically might have caused 
death if  it were more severe.  
Grade 5:  Fatal outco me. 
An event is defined as ‘serious’ when it meets at least 1 of t he predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality   
• The investigator is ob ligated to assess the relationship between study intervention 
(investigational drug and/or study procedures) each occurrence of each AE/SAE 
according to the categories below.  
• A “reasonable possibility” of a relationship conveys that there are facts, eviden ce, 
and/or arguments to suggest a causal re lationship, rather than a relationship cannot 
be ruled  out. 
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and ot her 
risk factors, as well as the temporal r elationship of the event to study intervention 
adminis tration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed produ cts, in his/her assessment.  
 
1 Please refer to the CTCAE v5 at: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quic k_Reference
_5x7.pdf .  
Accessed April 19, 2019  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 61 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
• For each AE/SAE , the investigator must  document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality in terms of 
whether the AE/SAE may be related to study intervention and/or stud y procedures.  
• There may be situations in wh ich an SAE has occurred, and the investigator has 
minimal information to include in the initial report to the Sponsor. However, it is 
very important that the investigator always assess causality for every event 
before the initi al transmission of the SAE da ta to the Sponsor  
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send a SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one o f the criteria  used when determining regula tory 
reporting requirements.  
Causality Categories:  
Related : The AE follows  a reasonable temporal sequence from the time of study drug 
administration and/or follows a known response to the study drug and cannot be  reasonably 
explained by [CONTACT_770675]'s clinical state or other therapeutic interventions, 
or concomitant drugs administered to the subject.  
Not related : The AE is clearly related to other factors such as the subject’s clinical state, 
therapeutic interventions or concomitant dr ugs administered to the subject. There is no 
temporal relationship between the study drug and event onset. This is especially so when an 
event occurs prior to the commencement of treatment with the study drug.  
 
Follow-up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by  [CONTACT_14356]/or causality of the AE or SAE as 
fully as possible. This may i nclude additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.  
• If a subject  dies during participation in the study or during a recognized  follow -up 
period, the Investigator  will p rovide the Sponsor  with a copy of any postmortem 
findings including histopathology , if available . 
• New or updated information will be recorded in the originally completed CRF.  
• The Investigator  will submit any update d SAE data to  the Sponsor or designee  
within 24 hours of receipt of the information.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 62 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.3.4.  Reporting of SAEs  
SAE Reporting to  Medical Monitor  via an Electronic Data Collection Tool  
• The primary mechanism for initial reporting of an SAE to Sponsor or designee  will 
be the electronic case report form (eCRF ). 
• If the eCRF  is unavailable, then the site will use the paper SAE data collection tool 
(see next section) in order to report the event within 24 hours.  
• The site will enter the SAE data into the eCRF  as soon a s it becomes available.  
• After the study is com pleted at a given site, the eCRF  will be taken off -line to 
prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study subject  or receives updated 
data on a previously reported SAE after the electronic d ata collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the Medical Monitor  by [CONTACT_756].  
• Contacts for SAE reporting can be found in  the relevant site manual . 
  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 63 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.4. Appendix 4: Contra ceptive Guidance and Collection of Pregnancy 
Information  
10.4.1.  Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently s terile (see below).  
If fertility is unclear  (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study drug, additional evaluation should be considered . 
Women in the following categories are not consi dered WOCBP  
1. Premenarchal  
2. Premenopausal fema le with 1 of the following:  
− Documented hysterectomy  
− Documented bilateral salpi[INVESTIGATOR_1656]  
− Documented bilateral oophorectomy  
For individuals with permanent infertility du e to a medical cause other than the above,  (e.g., 
Mullerian  agenesis, androgen insensitivi ty), Investigator  discretion should be applied to 
determining study entry.  
Note: Documentation can come from the site personnel’s review of the subject ’s medical 
records, medical examination, or medical history in terview.  
Postmenopausal female  
• A postmenopa usal state is defined as  having had  no menses for 1 year  without an 
alternative medical cause.  
− A high follicle stimulating hormone (FSH) level in the postmenopausal r ange may 
be used to confirm a postmenopausal st ate in women not using hormonal 
contracepti on or hormonal replacement therapy (HRT). However, in the absence 
of 1 year  of amenorrhea, confirmation with more than one FSH measurement is 
required . 
• Females on HRT and whose menopausal status is in doubt will b e required to use one 
of the non -estrogen h ormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of p ostmenopausal status before study enrollment.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 64 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.4.2.  Cont raception Guidance  
Male Subjects:  
Male subj ects are eligible to participate if they agree to the following from informed consent, 
during the treatment  period and for [ADDRESS_1126634] dose of study dru g: 
• Refrain from donating sperm  
PLUS , either : 
• Be ab stinent from heterosexual intercourse as th eir preferred and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent  
OR 
• Must agree to use contraception/barrier as detailed below  
− Agree to use a male condom  
Female Subjec ts: 
• A female subject is eligible to partici pate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:  
− Is not a woman of childbearing potential (WOCBP)  
OR 
− Is a WOCBP and using a contraceptive method that is highly ef fective (with a 
failure rate of <  1% per ye ar), preferably with low user dependency (see table 
below), at least [ADDRESS_1126635] dose of study drug, and agrees not to donate eggs (ov a, 
oocytes) for the purpose of reproduction  during this period. The investigator 
should evaluate the effectiveness of the contraceptive method in relationship to  the 
first dose of study drug.  
− A WOCBP must have negative serum pregnancy test (minimum sensiti vity 
25 IU/L or equivalent units of human c horionic gonadotropin [HCG]) within [ADDRESS_1126636] administration of study drug.  
− If a urine tes t cannot be confirmed as negative ( e.g., an ambiguous result), a serum 
pregnancy test is requir ed, and results must be negative. In such c ases, the subject 
must be excluded from participation if the serum pregnancy result is positive.  
Contraceptive use by [CONTACT_813581]. 
Note: Ethinyl estradiol is the primary estrogen used in hormonal contraceptives. The progestin 
component consis ts of norethindrone, levonorgestrel, norgestrel, norethindrone acetate, 
ethynodiol diacetate, n orgestimate, desogestrel, and drospi[INVESTIGATOR_187306].  As BLD -2660 is a weak 
CYP3A4 inducer, exposure to both the estrogen and progestin components in hormonal 
contraceptiv es may be decreased, resulting in an increased risk of pregnancy. As such, it is 
recommended th at subjects who are on hormonal contracepti ves for birth control should use an 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 65 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
alternate means of contraception (condoms, diaphragms, IUD, other barrier methods,  sexual 
abstinence, etc.) during participation in the study.  
 
10.4.3.  Collection of Pregnancy Informati on 
• In the event of a pregnancy, the female subject or partner of a male study subject 
should be referred to an obstetrician/gynecologist experienced in reproduct ive 
toxicity for further evaluation and counseling.  
• The Investigator will follow the female sub ject or partner of a male study subject unt il 
completion of the pregnancy  
• The Investigator must notify the Sponsor’s Medical Monitor of the outcome within 5 
days. 
• The Investigator will provide this information as a follow -up to the initial report.  
• If the o utcome of the pregnancy meets the criteria for immediate classification as an 
SAE (e.g., spontaneous abortion [any congenital anomaly detected in an aborted fetu s 
is to be documented], stillbirth, neonatal death, or congenital anomaly), then the 
Investigat or should report it as such.  
• All neonatal d eaths that occur within [ADDRESS_1126637] to causality, as SAEs. In addition, any in fant death after 30 days that the 
Investigator suspects is related to the in-utero  exposure to the study drug should also 
be reported.  
 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 66 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.5. Appendix 5: Cardiac Monitoring Protocol  
All troponin elevations and cardiac AEs and SAEs will be reviewed by [CONTACT_1363].  
Subjects with elevated troponins will be questioned regarding occurrence of any cardiac 
symptoms . The symptoms will be evaluated by a stud y investigator and a consulting physician 
independent of the inv estigator team who will recommend whether any additional studies should 
be performed . In addition, during the evaluation period:  
1. Study drug could be w ithheld, at the discretion of the investig ator 
2. Serum troponin, Creatine Kinase -Myocardial Band (CK -MB), my oglobin, 
comprehensive metabolic panel (including AST) will be obtained and 
echocardiogram and ECG performed and interpreted  
3. Detailed history of poten tial causes of troponin elevation should b e obtained  
4. Additional work up will be initiated per the Investig ator’s discretion and 
cardiology consultant  
If work up is negative, as determined by [CONTACT_18615]/or Medical Monitor , no further action 
is required and, if the study drug had been stopped,  it may be restarted.  
If work up is positive for a cardiac sourc e, the DMC will review and determine whether the study 
drug should be permanently discontinued and advise on any next ste ps, if any . 
 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 67 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.6. Appendix 6: Abbreviations  
Abbreviation Term  Description  
ACE -[ADDRESS_1126638] cancer resistance protein  
BID Twice per day  
BUN  Blood urea nitrogen  
CAPN  Small molecule inhibitor of calpain  
CFR  Case fatality rate  
CIOMS  Council for International Organiza tions of Medical Sciences  
CMH  Cochran –Mantel –Haenszel  
COVID -[ADDRESS_1126639] Computed tomography  
CTCAE  Common terminology criteria for ad verse events  
CYP  Cytochrome P450  
ECG  Electrocardiogram  
ECMO  Extra corporeal membrane oxygenation  
eCRF  Electronic case report form  
EOS  End of Study  
EOT  End of Treatment  
ET Early termination  
EUA  Emergency use authorization  
FAS Full analysis set  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126640]   
HIV Human Immunodeficiency Virus  
hsCRP  high sensitivity C -reactive  protein  
IB Investigator’s brochure  
ICF Informed consent form  
IEC Independent Ethics Committees  
INR International normalized ratio  
IPF Idiopathic pulmonary fibrosis  
IRT Inter active Response Technology  
ITT Intent -treat Set  
IUD Intrauterine dev ice 
JAKi  Janus kinase inhibitor  
LAM  Lactational amenorrhoea method  
LDH  Lactate dehydrogenase  
LS Least square  
MAD  Multiple ascending dose  
MedDRA  Medical Dictionary for Regulatory  Activities  
MITT  Modified intent -to-treat sect  
MMRM  Mixed measures re peated model  
NEWS  National Early Warning Score  
NGT  Naso -gastric tube  
NOAEL  No observed adverse effects level  
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126641]  Upper limit of normal  
WBC  White blood cell count  
WOCBP  Women of childbearing potential  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 70 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
10.7. Appendix 7: Protocol Amendment History  
Prior Amendments  
Blade has introduced the following modifications to Protocol Version 2.0. These c hanges are 
presented in order  of appearance :  
Amendment 1, 23 April 2020  
Overall Rationale for the Amendment:  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis  
3.0 Obje ctives and endpoints  • Reorganize objectives and endpoints  
• For oxygenatio n endpoints, added 
definition for medically fit for removal 
of oxygen  
• Changed mortality rate to be a secondary 
endpoint  
• Added Day 28 to relevant endpoints  • Per FDA request  
 
1.1 Synopsis  
1.2 Schedule of Activities  
4.0 Study Design  
8.3.1 Time Period and 
Frequency of Collection of 
AEs • Extended the study follow -up to Day 28  
• Added [ADDRESS_1126642] 
mortality , safety data  and forced vital 
capacity  • Per FDA request  
 
5.1.1 Inclusion Criteria  • Added oxygen requirements inclusion 
criteria  • Per FDA request  
 
5.1.2 Exclusion Criteria  • Modified supplement oxygen exclusion 
criteria  
• Added cross reference to the 
Concomitant Medication section of the 
protocol  
• Clarified excluded COVID therapi[INVESTIGATOR_813542]  • Based on 
Investigator’s 
input  
• For clarity and 
safety  measure  
 
6.6 Concomitant Therapy  • Updated restricted medications section to 
include azithromycin  
• Clarified to co nsult with Sponsor’s 
Medical Monitor prior to prescribing 
chloroquine, h ydroxychloroquine and 
azithromycin  
• Expanded section to include medicati ons 
affected by [CONTACT_813582] -2660  • Per FDA request  
• Safety precaution  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 71 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Section # and Name  [CONTACT_11029]  
1.2 Schedule of Activities  
8.1.2 Oxygenation Measures  • Clarified procedures for collecting 
oxygen saturation  • Per Investigator 
feedback  
1.2 Schedule of Activities  
8.1.4 Clinical Status Ordinal 
Score  • Changed to 6 -point ordinal scale by 
[CONTACT_813583] ‘not hospi[INVESTIGATOR_057]’ into 1 
category  • Per FDA request  
8.1.6 Hospi[INVESTIGATOR_813543]  • Clarified no rmal oxygen saturation 
criteria  
• Clarified oxygen supplementation status  
will be captured in the database  • Per FDA request  
8.2.1 Physical examinations  • Clarified text  • For clarity  
1.2 Schedule of Activities  
8.4 Pharmacokinetics (PK)  • Clarified that PK samples  will also be 
collected after first naso -gastric tube 
(NGT) is inserted  • To allow 
characterization 
of BLD -2660 
using NGT route 
of administration  
1.2 Schedule of Activities  • Update visit window  
• Remove biomarker blood sampling at 
screening as well as INR, uri nalysis and 
chest x -ray/CT on Day 21  
• Add overall survival check  
• Other u pdates as reflected above (e.g., 
adding Day 28)  • To update per 
changes to 
protocol and to 
ensure 
consistency 
throughout 
protocol  
9 Statistical Consideration  • Added azithromycin use to ef ficacy 
analyses  
• Updated to 6 -point ordinal scale  
• Updated to reflect Day  28 as EOS  
• Revised interim analysis to include 
efficacy boundaries and sample size re -
estimation when 50% of subjects 
completed the study  • Per FDA request  
General  • Corrected typos, forma tting, style  
• Aligned changes across protocol  
• Updated Abbreviation (Appe ndix 6)  • For clarity and 
readability  
 
 
  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 72 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
11. REFERENCES  
Adhikari SP, Meng S, Wu YJ, et al. Epi[INVESTIGATOR_623], causes, clinical manifestation and diagnosis, 
prevention and con trol of coronavirus disease (COVID -19) during the early outbreak period: a 
scopi[INVESTIGATOR_17971]. Infect Dis Poverty. 2020;9(1):29.  
 
Ascierto PA, Fox BA, Urba WJ, et al. Insights from immuno -oncology: The Society for 
Immunotherapy of Cancer statement on access to  IL-6-targeting therapi[INVESTIGATOR_135297] -19. J 
Immunother Cancer,. 2020;Online pub lication, accessed on March 27, 2020 from 
https://www.sitcancer.org/research/covid -19-resource s/il-6-editorial . 
 
Bozym RA, Patel K, White C, et al. Calcium signals and calpain -dependent necrosis are essential 
for release of coxsackievirus B from polarized intestinal epi[INVESTIGATOR_1663]. Mol Biol Cell. 
2011;22(17):3010 -3021.  
 
Conti P, Ronconi G, Caraf fa A, et al. Induction of pro -inflammatory cytokines (IL -1 and IL -6) 
and lung inflammation by [CONTACT_119979] -19 (COVI -19 or SARS -CoV -2): anti -inflammatory 
strategies.  J Biol Regul Homeost Agents. 2020;34(2).  
 
Coomes EA, Haghbayan H. Interleukin -6 in COVID -19: A Systematic Review and Meta -
Analysis. medRxiv. 2020:2020.2003.2030.20048058.  
 
Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503 -508. 
 
Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with 
HFNC or NIV in mo derate to severe ARDS: a multi -center prospective cohort study. Crit Care. 
2020;24(1):28.  
 
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown app arent efficacy in 
treatment of COVID -19 associated pneumonia in clinical studies. Bioscience trends. 
2020;14(1):72 -73. 
 
Gong J, Dong H, Xia SQ, et al. Correlation Analysis Between Disease Severity and 
Inflammation -related Parameters in Patients with COVID -19 Pneumonia. medRxiv. 
2020:2020.2002.2025.20025643.  
 
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 73 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
Guan WJ, Ni ZY, Hu Y, et al. Clinical C haracteristics of Coronavirus Disease 2019 in China. N 
Engl J Med. 2020.  
 
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapi[INVESTIGATOR_813544] 2019 (COVID -19) outbreak - an update on the s tatus. Mil Med Res. 2020;7(1):11.  
 
Herold T, Jurinovic V, Arnreich C, et al. Level of IL -6 predicts respi[INVESTIGATOR_813545] -19 patients. medRxiv. 2020:2020.2004.2001.20047381.  
 
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z . Review of the Clinical Character istics of 
Coronavirus Disease 2019 (COVID -19). J Gen Intern Med. 2020.  
 
Kuba K, Imai Y, Ohto -Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin -
angiotensin system, a SARS receptor, and a partner for amino  acid transporters. Pharmacol Ther . 
2010;128(1):119 -128. 
 
Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID -
19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of internal 
medicine. 2020.  
 
Liu Y, Yan LM, Wan L, et al. Vira l dynamics in mild and severe cases of COVID -19. Lancet 
Infect Dis. 2020.  
 
Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United 
States veterans hospi[INVESTIGATOR_363095] -19. medRxiv. 2020:2020.2004.2016.20065920.  
 
Maheva s M, Tran V -T, Roumier M, et al. No evidence of clinical efficacy of 
hydroxychloroquine in patients hospi[INVESTIGATOR_191544] -19 infection with oxygen requirement: 
results of a study using routinely collected data to emulate a target trial. medRxiv. 
2020:2020 .2004.2010.20060699.  
 
McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including 
Interleukin -6 in COVID -19 induced Pneumonia and Macrophage Activation Syndrome -Like 
Disease. Autoimmun Rev. 2020:102537.  
 
 Study drug: BLD -2660  
Protocol Numb er: B-[ADDRESS_1126643]. 2005;128(3):1393 -1400.  
 
Peterson RL, Vock DM, Powers JH, et al. Analysis of an ordinal endpoint for use in evaluating 
treatments for severe influenza requir ing hospi[INVESTIGATOR_059]. Clin Trials. 2017;14(3):[ADDRESS_1126644] GR, et al. Comparison of the SpO2/FIO2 ratio and the 
PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132(2):410 -417. 
 
Rodriguez -Morales AJ, Cardona -Ospi[INVESTIGATOR_754272], Gutierrez -Ocampo E, et al. Clinical, laboratory and 
imaging features of COVID -19: A systematic review and meta -analysis. Travel Med Infect Dis. 
2020:101623.  
 
Rothan HA, By[CONTACT_41450]. The epi[INVESTIGATOR_813546] 
(COVI D-19) outbreak. J Autoimmun. 2020:102433.  
 
Smith GB, Prytherch DR, Jarvis S, et al. A Comparison of the Ability of the Physiologic 
Components of Medical Emergency Team Criteria and the U.K. National Early Warning Score 
to Discriminate Patients at Risk of a  Range of Adverse Clinical Outcomes. Crit C are Med. 
2016;44(12):2171 -2181.  
 
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077] 2019 
Novel Coronavirus –Infected Pneumonia in Wuhan, China. JAMA. 2020a;323(11):1061 -1069.  
 
Wan g J, Wang B, Yang J, et al. Advances in the  research of mechanism of pulmonary fibrosis 
induced by [CONTACT_675213] 2019 and the corresponding therapeutic measures. Zhonghua 
shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns. 2020b ;36:E006.  
 
Williams B. The National Early W arning Score 2 (NEWS2) in patients with hypercapnic 
respi[INVESTIGATOR_1399]. Clin Med (Lond). 2019;19(1):94 -95. 
 
Yoon SY, Ha YE, Choi JE, et al. Coxsackievirus B4 uses autophagy for replication after calpain 
activatio n in rat primary neurons. J Virol. 2008;82( 23):[ZIP_CODE] -[ZIP_CODE].  
 
Zou L, Ruan F, Huang M, et al. SARS -CoV -2 Viral Load in Upper Respi[INVESTIGATOR_813547]. N Engl J Med. 2020;382(12):1177 -1179.  
 Study drug: BLD -2660  
Protocol Numb er: B-2660 -204 
 
Confidential  Page 75 of 75 Version 3.0, Amendment 2.0 
  08 May 2020  
 
 
 
 
 